Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Alanine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA1 | P23415 | 1/20 | 0.59 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.59 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.59 |
| ▸ | GABRP | O00591 | 2/20 | 0.46 |
| ▸ | GABRD | O14764 | 2/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.46 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.46 |
| ▸ | GABRE | P78334 | 2/20 | 0.46 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.46 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.46 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.46 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.46 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alanine SCHEMBL14677168 | 1.00 | GLRA1 (0.59) | GLRA1SLC6A9OR51E2GABRPGABRD | |
| D-Alanine SCHEMBL1537294 | 1.00 | GLRA1 (0.59) | GLRA1SLC6A9OR51E2GABRPGABRD | |
| Alanine SCHEMBL6534719 | 1.00 | GLRA1 (0.59) | GLRA1SLC6A9OR51E2GABRPGABRD | |
| Alanine SCHEMBL17513685 | 1.00 | GLRA1 (0.59) | GLRA1SLC6A9OR51E2GABRPGABRD | |
| Alanine SCHEMBL1675385 | 1.00 | GLRA1 (0.59) | GLRA1SLC6A9OR51E2GABRPGABRD | |
| Alanine SCHEMBL25189736 | 1.00 | GLRA1 (0.59) | GLRA1SLC6A9OR51E2GABRPGABRD | |
| Alanine SCHEMBL2083490 | 1.00 | GLRA1 (0.59) | GLRA1SLC6A9OR51E2GABRPGABRD | |
| Alanine SCHEMBL819876 | 1.00 | GLRA1 (0.59) | GLRA1SLC6A9OR51E2GABRPGABRD | |
| Alanine SCHEMBL8383645 | 1.00 | GLRA1 (0.59) | GLRA1SLC6A9OR51E2GABRPGABRD | |
| Alanine SCHEMBL157005 | 1.00 | GLRA1 (0.59) | GLRA1SLC6A9OR51E2GABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 532 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240240209-A1 | SYNTHESIS OF ENANTIOPURE CIS-A-IRONE FROM A RENEWABLE CARBON SOURCE | Institut National des Sciences Appliquées de Toulouse (FR) | 2024-07-18 | — | — | US | claimed |
| CN-117838627-A | Ceftiofur crystal injection and preparation method thereof | 艾美科健（中国）生物医药有限公司 | 2024-04-09 | — | — | CN | claimed |
| CN-107997979-B | Preparation method of thermosensitive liposome with whitening effect | 苏州纳康生物科技有限公司 | 2021-02-05 | — | — | CN | claimed |
| US-20190135865-A1 | AGONIST AGENTS OF CD47 INDUCING PROGRAMMED CELL DEATH AND THEIR USE IN THE TREATMENTS OF DISEASES ASSOCIATED WITH DEFECTS IN PROGRAMMED CELL DEATH | SORBONNE UNIVERSITE (FR) | 2019-05-09 | — | — | US | claimed |
| US-20100041612-A1 | Fragments of the Glucagon-Like Peptide-1 and Uses Thereof | NEW ENGLAND MEDICAL CENTER HOSPITALS, INC. | 2010-02-18 | — | — | US | claimed |
| US-20090202982-A1 | BLOOD-VISCOSITY REDUCING AGENT | Hitosugi, Masahito (JP) | 2009-08-13 | — | — | US | claimed |
| US-20090124555-A1 | USE OF HISTOGRANIN AND HISTOGRANIN-LIKE COMPOUNDS AS INHIBITORS OF P2X7 RECEPTOR FUNCTION AND AS ANTI-ARTHRITIC AGENTS | BERNATCHEZ-LEMAIRE IRMA | 2009-05-14 | — | — | US | claimed |
| WO-2007030706-A1 | FRAGMENTS OF THE GLUCAGON-LIKE PEPTIDE-I AND USES THEREOF | NEW ENGLAND MEDICAL CENTER HOSPITALS, INC. (US) | 2007-03-15 | — | — | WO | claimed |
| EP-1027031-A2 | STABILIZED ALUMINIUM ZIRCONIUM ANTIPERSPIRANT COMPOSITIONS | Colgate-Palmolive Company (US) | 2000-08-16 | — | — | EP | claimed |
| US-6066314-A | AQUEOUS SOLUTIONS OF ALUMINUM ZIRCONIUM GLYCINE SALTS; SILOXANE POLYAMIDE GELLING AGENT; D4, D5 AND D6 CYCLOMETHICONES; AMINO ACID SELECTED FROM THE GROUP CONSISTING OF GLYCINE, ALANINE, THREONINE AND LEUCINE | COLGATE-PALMOLIVE COMPANY (US) | 2000-05-23 | — | — | US | claimed |
| WO-1999021528-A2 | STABILIZED ALUMINIUM ZIRCONIUM ANTIPERSPIRANT COMPOSITIONS | COLGATE-PALMOLIVE COMPANY (US) | 1999-05-06 | — | — | WO | claimed |
| EP-0832110-A1 | ANTIVIRAL PEPTOID COMPOUNDS | Novartis AG (CH) | 1998-04-01 | — | — | EP | claimed |
| WO-1996040759-A1 | ANTIVIRAL PEPTOID COMPOUNDS | NOVARTIS AG (CH) | 1996-12-19 | — | — | WO | claimed |
| US-5061806-A | Phosphinic acid derivatives | MERCK & CO., INC. (US) | 1991-10-29 | — | — | US | claimed |
| EP-0118280-B1 | ENZYME INHIBITION | Aktiebolaget Hässle (SE) | 1989-07-12 | — | — | EP | claimed |
| WO-1988006034-A1 | DERMAL COSMETIC COMPOSITION AND APPLICATIONS THEREFOR | FIASCHETTI MARY GEMMA (US) | 1988-08-25 | — | — | WO | claimed |
| WO-1984003507-A1 | ENZYME INHIBITION | FERRING AB (SE) | 1984-09-13 | — | — | WO | claimed |
| EP-0118280-A1 | Enzyme inhibition | Aktiebolaget Hässle (SE) | 1984-09-12 | — | — | EP | claimed |
| US-4238306-A | Electrodialysis process for the separation of non-essential amino acids from derivatives thereof | RESEARCH PRODUCTS REHOVOT LTD. (IL) | 1980-12-09 | — | — | US | claimed |
| JP-61100177-A | — | — | None | — | — | JP | disclosed |
| US-12042542-B2 | Synthetic antibody mimetic compounds (SYAMS) targeting cancer, especially prostate cancer | YALE UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240240197-A1 | HERBICIDE-TOLERANT PLANTS | BASF SE (DE) | 2024-07-18 | — | — | US | disclosed |
| US-20240240158-A1 | NOVEL 7Beta-HYDROXYSTEROID DEHYDROGENASE MUTANTS AND PROCESS FOR THE PREPARATION OF URSODEOXYCHOLIC ACID | PHARMAZELL GMBH (DE) | 2024-07-18 | — | — | US | disclosed |
| US-20240226309-A1 | HEAD AND NECK CANCER COMBINATION THERAPY COMPRISING AN IL-2 CONJUGATE AND CETUXIMAB | Synthorx, Inc. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228566-A1 | COMPOSITIONS AND METHODS FOR VASCULAR PROTECTION AFTER MYOCARDIAL ISCHEMIA | THE UNIVERSITY OF VERMONT AND STATE AGRICULTURE COLLEGE (US) | 2024-07-11 | — | — | US | disclosed |
| US-12023395-B2 | Xanthan structured high polyol liquid cleansers | CONOPCO, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| WO-2024137864-A1 | CANCER THERAPY WITH IL-2 CONJUGATES AND CHIMERIC ANTIGEN RECEPTOR THERAPIES | Synthorx, Inc. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024136899-A1 | CANCER THERAPY WITH IL-2 CONJUGATES AND CHIMERIC ANTIGEN RECEPTOR THERAPIES | Synthorx, Inc. (US) | 2024-06-27 | — | — | WO | disclosed |
| EP-3456820-B1 | New 7beta-hydroxysteriod dehydrogenase mutants and method for producing ursodeoxycholic acid | PHARMAZELL GMBH (DE) | 2024-06-19 | — | — | EP | disclosed |
| CN-111712517-B | IL-1 RAP-targeted CAR-T cells and their uses | 法国血液机构 | 2024-05-14 | — | — | CN | disclosed |
| US-11981935-B2 | 7β-hydroxysteroid dehydrogenase mutants and process for the preparation of ursodeoxycholic acid | PHARMAZELL GMBH (DE) | 2024-05-14 | — | — | US | disclosed |
| WO-2024086901-A1 | BIODEGRADABLE ELASTOMERIC ARTICLES AND METHODS FOR THEIR PRODUCTION | DIPTECH PTE LIMITED (SG) | 2024-05-02 | — | — | WO | disclosed |
| EP-4346904-A1 | HEAD AND NECK CANCER COMBINATION THERAPY COMPRISING AN IL-2 CONJUGATE AND CETUXIMAB | Synthorx, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4346903-A1 | HEAD AND NECK CANCER COMBINATION THERAPY COMPRISING AN IL-2 CONJUGATE AND PEMBROLIZUMAB | Synthorx, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117838627-A | Ceftiofur crystal injection and preparation method thereof | 艾美科健（中国）生物医药有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-117838627-A | Ceftiofur crystal injection and preparation method thereof | 艾美科健（中国）生物医药有限公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20240082411-A1 | T-Cell Modulatory Polypeptides with Conjugation Sites and Methods of Use Thereof | CUE BIOPHARMA, INC. | 2024-03-14 | — | — | US | disclosed |
| US-20240082359-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | Synthorx, Inc. (US) | 2024-03-14 | — | — | US | disclosed |
| US-11919934-B2 | IL-15 conjugates and uses thereof | Synthorx, Inc. (US) | 2024-03-05 | — | — | US | disclosed |
| US-20240067984-A1 | TRIPLE FUNCTION ADENO-ASSOCIATED VIRUS (AAV)VECTORS FOR THE TREATMENT OF C9ORF72 ASSOCIATED DISEASES | APPLIED GENETIC TECHNOLOGIES CORPORATION | 2024-02-29 | — | — | US | disclosed |
| EP-3899532-B1 | A LABELLING METHOD TO DISTINGUISH ISOBARIC AMINO ACIDS AND AMINO ACID COMBINATIONS | RAPID NOVOR INC (CA) | 2024-02-14 | — | — | EP | disclosed |
| EP-4313089-A1 | BACTERIA ENGINEERED TO TREAT DISORDERS IN WHICH OXALATE IS DETRIMENTAL | Synlogic Operating Company, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| US-11879145-B2 | Reagents and methods for replication, transcription, and translation in semi-synthetic organisms | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-01-23 | — | — | US | disclosed |
| US-20230416327-A1 | IMMUNO ONCOLOGY THERAPIES WITH IL-2 CONJUGATES | Synthorx, Inc. (US) | 2023-12-28 | — | — | US | disclosed |
| EP-4291243-A1 | LUNG CANCER COMBINATION THERAPY WITH IL-2 CONJUGATES AND AN ANTI-PD-1 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF | Synthorx, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20230381335-A1 | LUNG CANCER COMBINATION THERAPY WITH IL-2 CONJUGATES AND AN ANTI-PD-1 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF | SYNTHORX INC (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230374088-A1 | PEPTIDE INHIBITORS OF GLIOMA-ASSOCIATED ONCOGENE DERIVED FROM THE COILED-COIL DIMERIZATION DOMAIN OF Kif7 | MASSACHUSETTS GEN HOSPITAL (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230355737-A1 | PARTICLE COMPRISING AN RSV-F PROTEIN FOR USE IN RSV VACCINATION | VIROMETIX AG (CH) | 2023-11-09 | — | — | US | disclosed |
| US-20230302089-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | Synthorx, Inc. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230279076-A1 | T-Cell Modulatory Polypeptides with Conjugation Sites and Methods of Use Thereof | CUE BIOPHARMA, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230277627-A1 | IMMUNO ONCOLOGY COMBINATION THERAPY WITH IL-2 CONJUGATES AND PEMBROLIZUMAB | Synthorx, Inc. (US) | 2023-09-07 | — | — | US | disclosed |
| CN-116635061-A | Immunooncology therapies with IL-2 conjugates | 新索思股份有限公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-116615247-A | Combination therapy of immunooncology with IL-2 conjugates and pembrolizumab | 新索思股份有限公司 | 2023-08-18 | — | — | CN | disclosed |
| EP-4225375-A1 | IMMUNO ONCOLOGY THERAPIES WITH IL-2 CONJUGATES | Synthorx, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-4225376-A1 | IMMUNO ONCOLOGY COMBINATION THERAPY WITH IL-2 CONJUGATES AND PEMBROLIZUMAB | Synthorx, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-4216992-A1 | PARTICLE COMPRISING AN RSV-F PROTEIN FOR USE IN RSV VACCINATION | DBV Technologies (FR) | 2023-08-02 | — | — | EP | disclosed |
| US-20230235395-A1 | CONFORMATIONAL PROBES AND METHODS FOR SEQUENCING NUCLEIC ACIDS | ILLUMINA, INC. | 2023-07-27 | — | — | US | disclosed |
| WO-2023137156-A2 | T CELL MODULATORY POLYPEPTIDES WITH CONJUGATION SITES AND METHODS OF USE THEREOF | CUE BIOPHARMA, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023137158-A2 | T CELL MODULATORY POLYPEPTIDES WITH CONJUGATION SITES AND METHODS OF USE THEREOF | CUE BIOPHARMA, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| US-11701407-B2 | Cytokine conjugates for the treatment of proliferative and infectious diseases | Synthorx, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| CN-116437952-A | T cell modulating polypeptides with conjugation sites and methods of use thereof | 库尔生物制药有限公司 | 2023-07-14 | — | — | CN | disclosed |
| WO-2023122573-A1 | HEAD AND NECK CANCER COMBINATION THERAPY COMPRISING AN IL-2 CONJUGATE AND PEMBROLIZUMAB | Synthorx, Inc. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023122750-A1 | CANCER COMBINATION THERAPY WITH IL-2 CONJUGATES AND CETUXIMAB | Synthorx, Inc. (US) | 2023-06-29 | — | — | WO | disclosed |
| CN-114478627-B | Allylated monophosphine ligand and preparation method thereof | 湖北大学 | 2023-06-20 | — | — | CN | disclosed |
| CN-116209465-A | Immunooncology combination therapy with IL-2 conjugates and anti-EGFR antibodies | 新索思股份有限公司 | 2023-06-02 | — | — | CN | disclosed |
| EP-4182465-A2 | T-CELL MODULATORY POLYPEPTIDES WITH CONJUGATION SITES AND METHODS OF USE THEREOF | Cue Biopharma, Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
| CN-116134134-A | Trifunctional adeno-associated virus (AAV) vectors for the treatment of C9ORF 72-related diseases | 应用遗传科技公司 | 2023-05-16 | — | — | CN | disclosed |
| US-11643684-B2 | Conformational probes and methods for sequencing nucleic acids | ILLUMINA, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| EP-4171648-A1 | IMMUNO ONCOLOGY COMBINATION THERAPY WITH IL-2 CONJUGATES AND ANTI-EGFR ANTIBODIES | Synthorx, Inc. (US) | 2023-05-03 | — | — | EP | disclosed |
| US-11622993-B2 | Cytokine conjugates for the treatment of autoimmune diseases | Synthorx, Inc. (US) | 2023-04-11 | — | — | US | disclosed |
| CN-115867578-A | Method for producing full-length antibody by using escherichia coli | 苏特罗生物制药公司 | 2023-03-28 | — | — | CN | disclosed |
| EP-4143233-A1 | METHODS OF PRODUCING FULL-LENGTH ANTIBODIES USING E.COLI | Sutro Biopharma, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| EP-4120997-A1 | TREATMENT OF UPPER FACIAL LINES | Ipsen Biopharm Limited (GB) | 2023-01-25 | — | — | EP | disclosed |
| EP-4118096-A1 | STABILISED VIRAL FUSION PROTEINS | Oxford University Innovation Limited (GB) | 2023-01-18 | — | — | EP | disclosed |
| WO-2022256538-A1 | HEAD AND NECK CANCER COMBINATION THERAPY COMPRISING AN IL-2 CONJUGATE AND CETUXIMAB | Synthorx, Inc. (US) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022256534-A1 | HEAD AND NECK CANCER COMBINATION THERAPY COMPRISING AN IL-2 CONJUGATE AND PEMBROLIZUMAB | Synthorx, Inc. (US) | 2022-12-08 | — | — | WO | disclosed |
| CN-115175704-A | Interleukin 10 conjugates and uses thereof | 新索思股份有限公司 | 2022-10-11 | — | — | CN | disclosed |
| CN-115144583-A | Novel antigens of milk allergy | 学校法人藤田学园 | 2022-10-04 | — | — | CN | disclosed |
| CN-114949240-A | IL-2 conjugates and methods of use thereof | 新索思股份有限公司 | 2022-08-30 | — | — | CN | disclosed |
| US-20220228148-A1 | EUKARYOTIC SEMI-SYNTHETIC ORGANISMS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-07-21 | — | — | US | disclosed |
| EP-4028060-A1 | IL-2 CONJUGATES AND METHODS OF USE TO TREAT AUTOIMMUNE DISEASES | Synthorx, Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| CN-114761026-A | Compositions and methods for in vivo synthesis of non-native polypeptides | 斯克利普斯研究所 | 2022-07-15 | — | — | CN | disclosed |
| CN-114746122-A | IL-2 conjugates and methods of use to treat autoimmune diseases | 新索思股份有限公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-114746099-A | Eukaryotic semisynthetic organisms | 斯克利普斯研究所 | 2022-07-12 | — | — | CN | disclosed |
| US-20220211877-A1 | COMPOUND FOR INTRAOPERATIVE MOLECULAR BIOIMAGING, METHOD OF MAKING THE SAME, USE THEREOF IN INTRAOPERATIVE MOLECULAR BIOIMAGING AND SURGICAL METHOD COMPRISING INTRAOPERATIVE MOLECULAR BIOIMAGING | TECHNISCHE UNIVERSITAT MUNCHEN (DE) | 2022-07-07 | — | — | US | disclosed |
| EP-4017540-A1 | IL-15 CONJUGATES AND USES THEREOF | Synthorx, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| EP-4013454-A1 | IMMUNO ONCOLOGY COMBINATION THERAPIES WITH IL-2 CONJUGATES | Synthorx, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| CN-114555128-A | Combination immunooncology therapy with IL-2 conjugates | 新索思股份有限公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-114555632-A | IL-15 conjugates and uses thereof | 新索思股份有限公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20220154209-A1 | PV-DELETED BOVINE ADENOVIRUS | UNIVERSITY OF SASKATCHEWAN (CA) | 2022-05-19 | — | — | US | disclosed |
| WO-2022099156-A2 | T-CELL MODULATORY POLYPEPTIDES WITH CONJUGATION SITES AND METHODS OF USE THEREOF | CUE BIOPHARMA, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| EP-3983543-A1 | REAGENTS AND METHODS FOR REPLICATION, TRANSCRIPTION, AND TRANSLATION IN SEMI-SYNTHETIC ORGANISMS | The Scripps Research Institute (US) | 2022-04-20 | — | — | EP | disclosed |
| WO-2022076853-A1 | IMMUNO ONCOLOGY COMBINATION THERAPY WITH IL-2 CONJUGATES AND PEMBROLIZUMAB | Synthorx, Inc. (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022076859-A1 | IMMUNO ONCOLOGY THERAPIES WITH IL-2 CONJUGATES | Synthorx, Inc. (US) | 2022-04-14 | — | — | WO | disclosed |
| CN-114207129-A | Agents and methods for replication, transcription and translation in semi-synthetic organisms | 斯克利普斯研究所 | 2022-03-18 | — | — | CN | disclosed |
| US-11242560-B2 | Apparatus and methods for kinetic analysis and determination of nucleic acid sequences | ILLUMINA, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20220026438-A1 | A LABELLING METHOD TO DISTINGUISH ISOBARIC AMINO ACIDS AND AMINO ACID COMBINATIONS | RAPID NOVOR INC. (CA) | 2022-01-27 | — | — | US | disclosed |
| US-20220016249-A1 | IL-2 Conjugates and Methods of Use Thereof | Synthorx, Inc. (US) | 2022-01-20 | — | — | US | disclosed |
| US-20220016252-A1 | IMMUNO ONCOLOGY COMBINATION THERAPY WITH IL-2 CONJUGATES AND ANTI-EGFR ANTIBODIES | Synthorx, Inc. (US) | 2022-01-20 | — | — | US | disclosed |
| WO-2022015880-A2 | T-CELL MODULATORY POLYPEPTIDES WITH CONJUGATION SITES AND METHODS OF USE THEREOF | CUE BIOPHARMA, INC. (US) | 2022-01-20 | — | — | WO | disclosed |
| WO-2021263026-A1 | IMMUNO ONCOLOGY COMBINATION THERAPY WITH IL-2 CONJUGATES AND ANTI-EGFR ANTIBODIES | Synthorx, Inc. (US) | 2021-12-30 | — | — | WO | disclosed |
| EP-3923974-A1 | IL-2 CONJUGATES AND METHODS OF USE THEREOF | Synthorx, Inc. (US) | 2021-12-22 | — | — | EP | disclosed |
| CN-113660946-A | IL-2 conjugates and methods of use thereof | 新索思股份有限公司 | 2021-11-16 | — | — | CN | disclosed |
| US-20210338829-A1 | INTERLEUKIN 10 CONJUGATES AND USES THEREOF | Synthorx, Inc. (US) | 2021-11-04 | — | — | US | disclosed |
| US-20210340586-A1 | Methods of Producing Full-Length Antibodies Using E. coli | SUTRO BIOPHARMA, INC. | 2021-11-04 | — | — | US | disclosed |
| WO-2021222719-A1 | METHODS OF PRODUCING FULL-LENGTH ANTIBODIES USING E.COLI | SUTRO BIOPHARMA, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| EP-3899532-A1 | A LABELLING METHOD TO DISTINGUISH ISOBARIC AMINO ACIDS AND AMINO ACID COMBINATIONS | Rapid Novor Inc. (CA) | 2021-10-27 | — | — | EP | disclosed |
| CN-113508298-A | Labeling method for distinguishing isobaric amino acid and amino acid combination | 快速诺凡公司 | 2021-10-15 | — | — | CN | disclosed |
| WO-2021186167-A1 | TREATMENT OF UPPER FACIAL LINES | IPSEN BIOPHARM LIMITED (GB) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021181121-A1 | STABILISED VIRAL FUSION PROTEINS | OXFORD UNIVERSITY INNOVATION LIMTIED (GB) | 2021-09-16 | — | — | WO | disclosed |
| EP-3876973-A1 | INTERLEUKIN 10 CONJUGATES AND USES THEREOF | Synthorx, Inc. (US) | 2021-09-15 | — | — | EP | disclosed |
| CN-113260374-A | Interleukin 10 conjugates and uses thereof | 新索思股份有限公司 | 2021-08-13 | — | — | CN | disclosed |
| US-11077195-B2 | IL-2 conjugates and methods of use thereof | Synthorx, Inc. (US) | 2021-08-03 | — | — | US | disclosed |
| CN-113173980-A | Antigens and epitopes of allergy | 朋友股份有限公司 | 2021-07-27 | — | — | CN | disclosed |
| CN-113030145-A | Method for selectively detecting target object by using nuclear spin singlet state | 华东师范大学 | 2021-06-25 | — | — | CN | disclosed |
| CN-113030815-A | Method for magnetic resonance spectrum detection of target object in designated space by utilizing nuclear spin singlet selectivity | 华东师范大学 | 2021-06-25 | — | — | CN | disclosed |
| CN-113030144-A | Method for realizing magnetic resonance imaging of target by utilizing nuclear spin singlet state and application | 华东师范大学 | 2021-06-25 | — | — | CN | disclosed |
| EP-3294908-B1 | METHODS FOR SEQUENCING NUCLEIC ACIDS | ILLUMINA INC (US) | 2021-06-23 | — | — | EP | disclosed |
| US-20210164040-A1 | CONFORMATIONAL PROBES AND METHODS FOR SEQUENCING NUCLEIC ACIDS | ILLUMINA, INC. (US) | 2021-06-03 | — | — | US | disclosed |
| EP-3828279-A1 | BIOCHEMICALLY ACTIVATED ELECTRONIC DEVICE | Illumina, Inc. (US) | 2021-06-02 | — | — | EP | disclosed |
| US-20210147873-A1 | TRIPLE FUNCTION ADENO-ASSOCIATED VIRUS (AAV)VECTORS FOR THE TREATMENT OF C9ORF72 ASSOCIATED DISEASES | APPLIED GENETIC TECHNOLOGIES CORPORATION | 2021-05-20 | — | — | US | disclosed |
| US-20210139862-A1 | NOVEL 7Beta-HYDROXYSTEROID DEHYDROGENASE MUTANTS AND PROCESS FOR THE PREPARATION OF URSODEOXYCHOLIC ACID | PHARMAZELL GMBH (DE) | 2021-05-13 | — | — | US | disclosed |
| WO-2021081236-A1 | TRIPLE FUNCTION ADENO-ASSOCIATED VIRUS (AAV) VECTORS FOR THE TREATMENT OF C9ORF72 ASSOCIATED DISEASES | APPLIED GENETIC TECHNOLOGIES CORPORATION (US) | 2021-04-29 | — | — | WO | disclosed |
| WO-2021072167-A1 | COMPOSITIONS AND METHODS FOR IN VIVO SYNTHESIS OF UNNATURAL POLYPEPTIDES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021067313-A1 | EUKARYOTIC SEMI-SYNTHETIC ORGANISMS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-04-08 | — | — | WO | disclosed |
| US-10954494-B2 | 7Beta-hydroxysteroid dehydrogenase mutants and process for the preparation of ursodeoxycholic acid | PHARMAZELL GMBH (DE) | 2021-03-23 | — | — | US | disclosed |
| WO-2021050554-A1 | IL-2 CONJUGATES AND METHODS OF USE TO TREAT AUTOIMMUNE DISEASES | Synthorx, Inc. (US) | 2021-03-18 | — | — | WO | disclosed |
| US-20210070827-A1 | IL-2 CONJUGATES AND METHODS OF USE TO TREAT AUTOIMMUNE DISEASES | Synthorx, Inc. (US) | 2021-03-11 | — | — | US | disclosed |
| WO-2021041206-A1 | IL-15 CONJUGATES AND USES THEREOF | Synthorx, Inc. (US) | 2021-03-04 | — | — | WO | disclosed |
| US-20210054040-A1 | NOVEL IL-15 CONJUGATES AND USES THEREOF | Synthorx, Inc. (US) | 2021-02-25 | — | — | US | disclosed |
| US-20210046160-A1 | Immuno Oncology Combination Therapies With IL-2 Conjugates | Synthorx, Inc. (US) | 2021-02-18 | — | — | US | disclosed |
| WO-2021030706-A1 | IMMUNO ONCOLOGY COMBINATION THERAPIES WITH IL-2 CONJUGATES | Synthorx, Inc. (US) | 2021-02-18 | — | — | WO | disclosed |
| US-10912836-B2 | Synthetic antibody mimetic compounds (SyAMs) targeting cancer, especially prostate cancer | YALE UNIVERSITY (US) | 2021-02-09 | — | — | US | disclosed |
| CN-107997979-B | Preparation method of thermosensitive liposome with whitening effect | 苏州纳康生物科技有限公司 | 2021-02-05 | — | — | CN | disclosed |
| US-20210017559-A1 | HEXURONATE C4-EPIMERASE VARIANT HAVING IMPROVED D-TAGATOSE CONVERSION ACTIVITY, AND D-TAGATOSE PRODUCTION METHOD USING SAME | CJ CHEILJEDANG CORPORATION (KR) | 2021-01-21 | — | — | US | disclosed |
| EP-3758729-A1 | IL-15 CONJUGATES AND USES THEREOF | Synthorx, Inc. (US) | 2021-01-06 | — | — | EP | disclosed |
| US-20200399338-A1 | IL-15 Conjugates and Uses Thereof | Synthorx, Inc. (US) | 2020-12-24 | — | — | US | disclosed |
| WO-2020252262-A1 | REAGENTS AND METHODS FOR REPLICATION, TRANSCRIPTION, AND TRANSLATION IN SEMI-SYNTHETIC ORGANISMS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-12-17 | — | — | WO | disclosed |
| US-20200392575-A1 | ENZYME-LINKED NUCLEOTIDES | ILLUMINA, INC. | 2020-12-17 | — | — | US | disclosed |
| US-20200392550-A1 | REAGENTS AND METHODS FOR REPLICATION, TRANSCRIPTION, AND TRANSLATION IN SEMI-SYNTHETIC ORGANISMS | THE SCRIPPS RESEARCH INSTITUTE | 2020-12-17 | — | — | US | disclosed |
| CN-112079909-A | Antigens and epitopes of allergy | 朋友股份有限公司 | 2020-12-15 | — | — | CN | disclosed |
| CN-112004547-A | IL-15 conjugates and uses thereof | 新索思股份有限公司 | 2020-11-27 | — | — | CN | disclosed |
| US-10837056-B2 | Conformational probes and methods for sequencing nucleic acids | ILLUMINA, INC. (US) | 2020-11-17 | — | — | US | disclosed |
| US-20200348257-A1 | BIOCHEMICALLY ACTIVATED ELECTRONIC DEVICE | ILLUMINA, INC. | 2020-11-05 | — | — | US | disclosed |
| EP-3460075-B1 | BIOCHEMICALLY ACTIVATED ELECTRONIC DEVICE | ILLUMINA INC (US) | 2020-11-04 | — | — | EP | disclosed |
| US-20200330601-A1 | IL-2 Conjugates and Methods of Use Thereof | Synthorx, Inc. (US) | 2020-10-22 | — | — | US | disclosed |
| US-10787704-B2 | Field-effect apparatus and methods for sequencing nucleic acids | ILLUMINA, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| CN-111712517-A | CAR-T cells targeting IL-1RAP and their uses | 法国血液机构 | 2020-09-25 | — | — | CN | disclosed |
| CN-111683719-A | Compounds for intraoperative molecular bioimaging, methods of making the same, uses thereof in intraoperative molecular bioimaging, and surgical methods comprising intraoperative molecular bioimaging | 慕尼黑工业大学伊萨尔河右岸医院 | 2020-09-18 | — | — | CN | disclosed |
| CN-111655716-A | IL-15-based fusions with IL-7 and IL-21 | 艾尔特生物科技公司 | 2020-09-11 | — | — | CN | disclosed |
| US-10767221-B2 | Enzyme-linked nucleotides | ILLUMINA, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| WO-2020163532-A1 | IL-2 CONJUGATES AND METHODS OF USE THEREOF | Synthorx, Inc. (US) | 2020-08-13 | — | — | WO | disclosed |
| US-20200246467-A1 | IL-2 CONJUGATES AND METHODS OF USE THEREOF | SYNTHORX INC (US) | 2020-08-06 | — | — | US | disclosed |
| US-20200231644-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | SANOFI (FR) | 2020-07-23 | — | — | US | disclosed |
| EP-2991677-B1 | SYNTHETIC ANTIBODY MIMETIC COMPOUNDS (SYAMS) TARGETING CANCER, ESPECIALLY PROSTATE CANCER | UNIV YALE (US) | 2020-07-15 | — | — | EP | disclosed |
| EP-3579815-B1 | XANTHAN STRUCTURED HIGH POLYOL LIQUID CLEANSERS | UNILEVER PLC (GB) | 2020-07-01 | — | — | EP | disclosed |
| WO-2020124252-A1 | A LABELLING METHOD TO DISTINGUISH ISOBARIC AMINO ACIDS AND AMINO ACID COMBINATIONS | RAPID NOVOR INC. (CA) | 2020-06-25 | — | — | WO | disclosed |
| CN-106231919-B | Preservation of perishable products based on biopolymers | 塔夫茨大学 | 2020-06-19 | — | — | CN | disclosed |
| US-20200188484-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | SANOFI (FR) | 2020-06-18 | — | — | US | disclosed |
| US-20200181220-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | SYNTHORX INC (US) | 2020-06-11 | — | — | US | disclosed |
| EP-3661956-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | Synthorx, Inc. (US) | 2020-06-10 | — | — | EP | disclosed |
| EP-3661955-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | Synthorx, Inc. (US) | 2020-06-10 | — | — | EP | disclosed |
| CN-111194322-A | Cytokine conjugates for the treatment of proliferative and infectious diseases | 辛索克斯公司 | 2020-05-22 | — | — | CN | disclosed |
| CN-111183149-A | Cytokine conjugates for the treatment of autoimmune diseases | 辛索克斯公司 | 2020-05-19 | — | — | CN | disclosed |
| US-10610571-B2 | Cytokine conjugates for the treatment of proliferative and infectious diseases | Synthorx, Inc. (US) | 2020-04-07 | — | — | US | disclosed |
| US-10605766-B2 | Biochemically activated electronic device | ILLUMINA, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| EP-3183338-B1 | NEURAL NETWORKS FORMED FROM CELLS DERIVED FROM PLURIPOTENT STEM CELLS | FUJIFILM CELLULAR DYNAMICS INC (US) | 2020-03-04 | — | — | EP | disclosed |
| CN-110799646-A | Antigens and epitopes of allergy | 朋友股份有限公司 | 2020-02-14 | — | — | CN | disclosed |
| US-10545115-B2 | Biochemically activated electronic device | ILLUMINA, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| CN-106434782-B | Method for producing cis-4-hydroxyproline | 南京工业大学 | 2020-01-10 | — | — | CN | disclosed |
| CN-105407920-B | Synthetic antibody mimetic compounds (SyAMs) targeting cancer, particularly prostate cancer | 耶鲁大学 | 2019-12-13 | — | — | CN | disclosed |
| US-20190323033-A1 | PV-DELETED BOVINE ADENOVIRUS | UNIVERSITY OF SASKATCHEWAN (CA) | 2019-10-24 | — | — | US | disclosed |
| US-20190314455-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | SANOFI (FR) | 2019-10-17 | — | — | US | disclosed |
| EP-3250926-B1 | SIMULTANEOUS CHARACTERIZATION OF IGG AND IGA ANTIBODIES TO MULTIPLE FOOD ANTIGENS AND C1Q-FOOD PROTEIN IMMUNE COMPLEXES | CYREX LABORATORIES LLC (US) | 2019-10-16 | — | — | EP | disclosed |
| US-10444227-B2 | Neural networks formed from cells derived from pluripotent stem cells | FUJIFILM Cellular Dynamics, Inc. (US) | 2019-10-15 | — | — | US | disclosed |
| US-10400310-B2 | Method for separation of rare earth ion | KABUSHIKI KAISHA TOYOTA CHUO KENKYUSHO (JP) | 2019-09-03 | — | — | US | disclosed |
| WO-2019165453-A1 | IL-15 CONJUGATES AND USES THEREOF | Synthorx, Inc. (US) | 2019-08-29 | — | — | WO | disclosed |
| CN-105198981-B | Osteogenic protein through designing | 惠氏有限责任公司 | 2019-07-16 | — | — | CN | disclosed |
| US-20190209696-A1 | SYNTHETIC ANTIBODY MIMETIC COMPOUNDS (SYAMS) TARGETING CANCER, ESPECIALLY PROSTATE CANCER | UNIV YALE (US) | 2019-07-11 | — | — | US | disclosed |
| CN-109837254-A | A kind of carbonyl reduction enzyme mutant that thermal stability improves | 中国科学院成都生物研究所 | 2019-06-04 | — | — | CN | disclosed |
| EP-3475435-A1 | PV-DELETED BOVINE ADENOVIRUS | University of Saskatchewan (CA) | 2019-05-01 | — | — | EP | disclosed |
| CN-109689870-A | Antibodies for the treatment of autoimmune diseases | 第一三共株式会社 | 2019-04-26 | — | — | CN | disclosed |
| WO-2019060921-A1 | METHODS OF GENERATING HIGHLY-CRYSTALLINE RECOMBINANT SPIDER SILK PROTEIN FIBERS | BOLT THREADS, INC. (US) | 2019-03-28 | — | — | WO | disclosed |
| EP-3460075-A1 | BIOCHEMICALLY ACTIVATED ELECTRONIC DEVICE | Illumina, Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| US-10233493-B2 | Conformational probes and methods for sequencing nucleic acids | ILLUMINA, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| WO-2019028419-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | Synthorx, Inc. (US) | 2019-02-07 | — | — | WO | disclosed |
| WO-2019028425-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | Synthorx, Inc. (US) | 2019-02-07 | — | — | WO | disclosed |
| US-20190002973-A1 | APPARATUS AND METHODS FOR KINETIC ANALYSIS AND DETERMINATION OF NUCLEIC ACID SEQUENCES | ILLUMINA, INC. (US) | 2019-01-03 | — | — | US | disclosed |
| CN-108912216-A | CAUSTIC STABLE CHROMATOGRAPHY LIGANDS | EMD密理博公司 | 2018-11-30 | — | — | CN | disclosed |
| CN-108864263-A | CAUSTIC STABLE CHROMATOGRAPHY LIGANDS | EMD密理博公司 | 2018-11-23 | — | — | CN | disclosed |
| CN-108864262-A | CAUSTIC STABLE CHROMATOGRAPHY LIGANDS | EMD密理博公司 | 2018-11-23 | — | — | CN | disclosed |
| US-10117943-B2 | Synthetic antibody mimetic compounds (SYAMS) targeting cancer, especially prostate cancer | YALE UNIVERSITY (US) | 2018-11-06 | — | — | US | disclosed |
| CN-108699536-A | OMEGA-HYDROXYLASE-RELATED FUSION POLYPEPTIDE VARIANTS WITH IMPROVED PROPERTIES | REG生命科学有限责任公司 | 2018-10-23 | — | — | CN | disclosed |
| US-20180298401-A1 | ENGINEERING PHOTOSYNTHESIS | CORNELL UNIVERSITY (US) | 2018-10-18 | — | — | US | disclosed |
| EP-3169805-B1 | BIOCHEMICALLY ACTIVATED ELECTRONIC DEVICE | ILLUMINA INC (US) | 2018-08-29 | — | — | EP | disclosed |
| WO-2018145827-A1 | XANTHAN STRUCTURED HIGH POLYOL LIQUID CLEANSERS | UNILEVER PLC (GB) | 2018-08-16 | — | — | WO | disclosed |
| EP-2004164-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING INFLAMMATORY DISEASES | NEUROTECH PHARMACEUTICALS CO LTD (KR) | 2018-08-08 | — | — | EP | disclosed |
| US-10022438-B2 | Method of enhancing KSHV LANA1 immunogenicity | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2018-07-17 | — | — | US | disclosed |
| CN-104672316-B | A kind of silk fibroin protein solution prepares and identification method | 苏州丝美特生物技术有限公司 | 2018-06-26 | — | — | CN | disclosed |
| US-20180155773-A1 | FIELD-EFFECT APPARATUS AND METHODS FOR SEQUENCING NUCLEIC ACIDS | ILLUMINA, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180155783-A1 | CONFORMATIONAL PROBES AND METHODS FOR SEQUENCING NUCLEIC ACIDS | ILLUMINA, INC. | 2018-06-07 | — | — | US | disclosed |
| CN-107961376-A | Nonsense mRNA degradeds are being treated and the application in diagnosis of neurodegenerative diseases | 中国科学院上海生命科学研究院 | 2018-04-27 | — | — | CN | disclosed |
| US-20180112265-A1 | BIOCHEMICALLY ACTIVATED ELECTRONIC DEVICE | ILLUMINA, INC. | 2018-04-26 | — | — | US | disclosed |
| US-9932568-B2 | Peptide linkers for polypeptide compositions and methods for using same | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| EP-3294908-A1 | FIELD-EFFECT APPARATUS AND METHODS FOR SEQUENCING NUCLEIC ACIDS | Illumina, Inc. (US) | 2018-03-21 | — | — | EP | disclosed |
| CN-107750336-A | Characterized while IgG and IgA antibody and C1Q food proteins immune complexs to a variety of food antigens | 西瑞斯实验室有限公司 | 2018-03-02 | — | — | CN | disclosed |
| EP-2971071-B1 | ENZYME-LINKED NUCLEOTIDES | ILLUMINA INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-9862998-B2 | Conformational probes and methods for sequencing nucleic acids | ILLUMINA, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| WO-2017221075-A1 | pV-DELETED BOVINE ADENOVIRUS | UNIVERSITY OF SASKATCHEWAN (CA) | 2017-12-28 | — | — | WO | disclosed |
| EP-3250926-A1 | SIMULTANEOUS CHARACTERIZATION OF IGG AND IGA ANTIBODIES TO MULTIPLE FOOD ANTIGENS AND C1Q-FOOD PROTEIN IMMUNE COMPLEXES | Cyrex Laboratories, LLC (US) | 2017-12-06 | — | — | EP | disclosed |
| US-20170247769-A1 | BIOSENSORS AND METHODS OF USE | CARNEGIE INSTITUTION OF WASHINGTON | 2017-08-31 | — | — | US | disclosed |
| CN-107109387-A | Prevention or treatment tissue or the recombination fusion protein of organ adhesion | 阿克森有限责任公司 | 2017-08-29 | — | — | CN | disclosed |
| CN-107048327-A | A kind of preparation method of nature bone balm | 天津农学院 | 2017-08-18 | — | — | CN | disclosed |
| EP-3183338-A1 | NEURAL NETWORKS FORMED FROM CELLS DERIVED FROM PLURIPOTENT STEM CELLS | Cellular Dynamics International, Inc. (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-3169805-A2 | BIOCHEMICALLY ACTIVATED ELECTRONIC DEVICE | Illumina, Inc. (US) | 2017-05-24 | — | — | EP | disclosed |
| CN-106604990-A | Omega-hydroxylase-related fusion polypeptides with improved properties | REG生命科学有限责任公司 | 2017-04-26 | — | — | CN | disclosed |
| CN-103211824-B | Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases | 纽若泰克制药株式会社 | 2017-04-19 | — | — | CN | disclosed |
| CN-102151330-B | Vaccine and method for treatment of motor neurone diseases | 耶达研究及发展有限公司 | 2017-04-12 | — | — | CN | disclosed |
| CN-106434782-A | Method for producing CIS-4-hydroxyproline | 南京工业大学 | 2017-02-22 | — | — | CN | disclosed |
| EP-3129408-A1 | HALF-LIFE EXTENDED FACTOR FVIIA PROTEIN FOR PREVENTION AND TREATMENT OF BLEEDING AND DOSING REGIMENS THEREFOR | CSL Limited (AU) | 2017-02-15 | — | — | EP | disclosed |
| US-9562911-B2 | Simultaneous characterization of IgG and IgA antibodies to multiple food antigens and C1Q-food protein immune complexes | CYREX LABORATORIES, LLC (US) | 2017-02-07 | — | — | US | disclosed |
| US-20170015978-A1 | Novel 7Beta-Hydroxysteroid Dehydrogenase Mutants and Process for the Preparation of Ursodeoxycholic Acid | PHARMAZELL GMBH (DE) | 2017-01-19 | — | — | US | disclosed |
| CN-106279715-A | A kind of copper peptide Porous coordination polymer and its preparation method and application | 武汉大学 | 2017-01-04 | — | — | CN | disclosed |
| EP-3102611-A1 | HUMANIZED BETA-AMYLOID BINDING MOLECULES AND USES THEREOF | Cangene Corporation (CA) | 2016-12-14 | — | — | EP | disclosed |
| CN-106231919-A | The preservation of perishable farm products based on biopolymer | 塔夫茨大学 | 2016-12-14 | — | — | CN | disclosed |
| CN-106164097-A | Half-life extended factor FVIIA for the prevention and treatment of bleeding and dosing regimens therefor | 杰特有限公司 | 2016-11-23 | — | — | CN | disclosed |
| US-20160331833-A1 | Method of Enhancing KSHV LANA1 Immunogenicity | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2016-11-17 | — | — | US | disclosed |
| WO-2016183218-A1 | FIELD-EFFECT APPARATUS AND METHODS FOR SEQUENCING NUCELIC ACIDS | ILLUMINA, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
| US-20160320403-A1 | SIMULTANEOUS CHARACTERIZATION OF IgG AND IgA ANTIBODIES TO MULTIPLE FOOD ANTIGENS AND C1Q-FOOD PROTEIN IMMUNE COMPLEXES | CYREX LABORATORIES, LLC | 2016-11-03 | — | — | US | disclosed |
| EP-3086804-A1 | FUSION PROTEINS COMPRISING FACTOR IX FOR PROPHYLACTIC TREATMENT OF HEMOPHILIA AND METHODS THEREOF | CSL Limited (AU) | 2016-11-02 | — | — | EP | disclosed |
| US-9469787-B2 | Nickel phosphorous CMP compositions and methods | CABOT MICROELECTRONICS CORPORATION (US) | 2016-10-18 | — | — | US | disclosed |
| US-20160298186-A1 | CONFORMATIONAL PROBES AND METHODS FOR SEQUENCING NUCLEIC ACIDS | ILLUMINA, INC. (US) | 2016-10-13 | — | — | US | disclosed |
| US-9452972-B2 | Methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof | XENOPORT, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| CN-105916877-A | Long-acting insulin and application thereof | 韩美药品株式会社 | 2016-08-31 | — | — | CN | disclosed |
| CN-105849262-A | Anti-LPS 011 antibody | 第三共株式会社 | 2016-08-10 | — | — | CN | disclosed |
| WO-2016122597-A1 | SIMULTANEOUS CHARACTERIZATION OF IGG AND IGA ANTIBODIES TO MULTIPLE FOOD ANTIGENS AND C1Q-FOOD PROTEIN IMMUNE COMPLEXES | CYREX LABORATORIES, LLC (US) | 2016-08-04 | — | — | WO | disclosed |
| US-9402895-B2 | Method of enhancing KSHV LANA1 immunogenicity | University of Pittsburg—Of the Commonwealth System of Higher Education (US) | 2016-08-02 | — | — | US | disclosed |
| US-20160177419-A1 | METHOD FOR SEPARATION OF RARE EARTH ION | KABUSHIKI KAISHA TOYOTA CHUO KENKYUSHO (JP) | 2016-06-23 | — | — | US | disclosed |
| US-20160168633-A1 | APPARATUS AND METHODS FOR KINETIC ANALYSIS AND DETERMINATION OF NUCLEIC ACID SEQUENCES | ILLUMINA, INC. (US) | 2016-06-16 | — | — | US | disclosed |
| US-20160152959-A1 | PEPTIDE LINKERS FOR POLYPEPTIDE COMPOSITIONS AND METHODS FOR USING SAME | SHIRE HUMAN GENETIC THERAPIES, INC. | 2016-06-02 | — | — | US | disclosed |
| US-9353412-B2 | Conformational probes and methods for sequencing nucleic acids | ILLUMINA, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| WO-2016077589-A1 | ENGINEERING PHOTOSYNTHESIS | CORNELL UNIVERSITY (US) | 2016-05-19 | — | — | WO | disclosed |
| US-20160116459-A1 | NEURAL NETWORKS FORMED FROM CELLS DERIVED FROM PLURIPOTENT STEM CELLS | CELLULAR DYNAMICS INTERNATIONAL, INC. (US) | 2016-04-28 | — | — | US | disclosed |
| WO-2016061116-A1 | NICKEL PHOSPHOROUS CMP COMPOSITIONS AND METHODS | CABOT MICROELECTRONICS CORPORATION (US) | 2016-04-21 | — | — | WO | disclosed |
| US-20160102227-A1 | NICKEL PHOSPHOROUS CMP COMPOSITIONS AND METHODS | CMC MATERIALS LLC | 2016-04-14 | — | — | US | disclosed |
| US-20160082112-A1 | SYNTHETIC ANTIBODY MIMETIC COMPOUNDS (SYAMS) TARGETING CANCER, ESPECIALLY PROSTATE CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-24 | — | — | US | disclosed |
| US-20160083738-A1 | PRODUCTION OF BACTERIAL MICROCOMPARTMENTS IN EUKARYOTIC CELLS | CORNELL UNIVERSITY (US) | 2016-03-24 | — | — | US | disclosed |
| CN-105407920-A | Synthetic antibody mimetic compounds (SyAMs) targeting cancer, especially prostate cancer | UNIV YALE | 2016-03-16 | — | — | CN | disclosed |
| EP-2991677-A1 | SYNTHETIC ANTIBODY MIMETIC COMPOUNDS (SYAMS) TARGETING CANCER, ESPECIALLY PROSTATE CANCER | Yale University (US) | 2016-03-09 | — | — | EP | disclosed |
| US-9279154-B2 | Apparatus and methods for kinetic analysis and determination of nucleic acid sequences | ILLUMINA, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| WO-2016028880-A1 | NEURAL NETWORKS FORMED FROM CELLS DERIVED FROM PLURIPOTENT STEM CELLS | CELLULAR DYNAMICS INTERNATIONAL, INC. (US) | 2016-02-25 | — | — | WO | disclosed |
| US-20160032379-A1 | ENZYME-LINKED NUCLEOTIDES | ILLUMINA, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160017416-A1 | BIOCHEMICALLY ACTIVATED ELECTRONIC DEVICE | ILLUMINA, INC (US) | 2016-01-21 | — | — | US | disclosed |
| WO-2016010975-A2 | BIOCHEMICALLY ACTIVATED ELECTRONIC DEVICE | ILLUMINA, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| EP-2971071-A1 | ENZYME-LINKED NUCLEOTIDES | Illumina, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9238680-B2 | Engineering heat-stable disease resistance in plants | CORNELL UNIVERSITY (US) | 2016-01-19 | — | — | US | disclosed |
| EP-2578206-B1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DISORDERS OF THE LOWER SECTION OF THE UROGENITAL SYSTEM | OBSHESTVO S OGRANICHENNOJ OTVETSTVENNOSTJU CYTONIR (RU) | 2015-12-09 | — | — | EP | disclosed |
| WO-2015154139-A1 | HALF-LIFE EXTENDED FACTOR FVIIA PROTEIN FOR PREVENTION AND TREATMENT OF BLEEDING AND DOSING REGIMENS THEREFOR | CSL LIMITED (AU) | 2015-10-15 | — | — | WO | disclosed |
| WO-2015113169-A1 | HUMANIZED BETA-AMYLOID BINDING MOLECULES AND USES THEREOF | CNJ HOLDINGS, INC. (CA) | 2015-08-06 | — | — | WO | disclosed |
| US-20150197486-A9 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2015-07-16 | — | — | US | disclosed |
| WO-2015095925-A1 | FUSION PROTEINS COMPRISING FACTOR IX FOR PROPHYLACTIC TREATMENT OF HEMOPHILIA AND METHODS THEREOF | CSL LIMITED (AU) | 2015-07-02 | — | — | WO | disclosed |
| US-8952006-B2 | Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use | XENOPORT, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| EP-2812319-A1 | MORPHOLINOALKYL FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE | XenoPort, Inc. (US) | 2014-12-17 | — | — | EP | disclosed |
| WO-2014182968-A2 | PRODUCTION OF BACTERIAL MICROCOMPARTMENTS IN EUKARYOTIC CELLS | CORNELL UNIVERSITY (US) | 2014-11-13 | — | — | WO | disclosed |
| US-20140329818-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | XENOPORT INC (US) | 2014-11-06 | — | — | US | disclosed |
| WO-2014178878-A1 | SYNTHETIC ANTIBODY MIMETIC COMPOUNDS (SYAMS) TARGETING CANCER, ESPECIALLY PROSTATE CANCER | YALE UNIVERSITY (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014142981-A1 | ENZYME-LINKED NUCLEOTIDES | ILLUMINA, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-8785443-B2 | Methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof | XENOPORT, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8778991-B2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XENOPORT, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140127749-A1 | METHODS OF PROTEIN PRODUCTION AND COMPOSITIONS THEREOF | ARIZONA BORAD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZO (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140087421-A1 | NOVEL 7Beta-HYDROXYSTEROID DEHYDROGENASE MUTANTS AND PROCESS FOR THE PREPARATION OF URSODEOXYCHOLIC ACID | PHARMAZELL GMBH (DE) | 2014-03-27 | — | — | US | disclosed |
| CN-103619174-A | Aqueous solutions of 1,2-benzisothiazolin-3-one | ISP INVESTMENTS INC | 2014-03-05 | — | — | CN | disclosed |
| US-20140056870-A1 | FUSION PROTEINS | ALLERGAN, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140051705-A1 | Morpholinoalkyl Fumarate Compounds, Pharmaceutical Compositions, and Methods of Use | XENOPORT, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8598383-B2 | Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2013-12-03 | — | — | US | disclosed |
| US-20130316988-A1 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2013-11-28 | — | — | US | disclosed |
| US-8580922-B2 | Peptide linkers for polypeptide compositions and methods for using same | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130280745-A1 | HIGH-THROUGHPUT, SENSITIVE DETECTION OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2013-10-24 | — | — | US | disclosed |
| EP-2650279-A2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XenoPort, Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| EP-2643474-A1 | HIGH-THROUGHPUT, SENSITIVE DETECTION OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE | Dh Technologies Development Pte. Ltd. (SG) | 2013-10-02 | — | — | EP | disclosed |
| CN-101437414-B | Antimicrobial preparations | PURAC BIOCHEM NV | 2013-10-02 | — | — | CN | disclosed |
| CN-101678318-B | Graft copolymer for cation-exchange chromatography | MERCK PATENT GMBH | 2013-09-25 | — | — | CN | disclosed |
| WO-2013119791-A1 | MORPHOLINOALKYL FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE | XENOPORT, INC. (US) | 2013-08-15 | — | — | WO | disclosed |
| US-20130203753-A1 | MORPHOLINOALKYL FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE | XENOPORT, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| WO-2013096692-A1 | APPARATUS AND METHODS FOR KINETIC ANALYSIS AND DETERMINATION OF NUCLEIC ACID SEQUENCES | ILLUMINA, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20130165328-A1 | APPARATUS AND METHODS FOR KINETIC ANALYSIS AND DETERMINATION OF NUCLEIC ACID SEQUENCES | ILLUMINA, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8455470-B2 | Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases | NEUROTECH PHARMACEUTICALS CO., LTD (KR) | 2013-06-04 | — | — | US | disclosed |
| CN-101426484-B | Application of pharmaceutical composition in preparation of medicines for treating or preventing degenerative and inflammatory diseases | NEUROTECH CO LTD | 2013-05-22 | — | — | CN | disclosed |
| US-20130059364-A1 | CULTIVATION OF DISPERSED MYCOBACTERIA | NOVARTIS VACCINES AND DIAGNOSTICS GMBH (DE) | 2013-03-07 | — | — | US | disclosed |
| US-20120308525-A1 | NUTRITIONAL COMPOSITIONS INCLUDING A HIGH PROTEIN COMPONENT AND EXOGENOUS NUCLEOTIDES | NESTEC S.A. (CH) | 2012-12-06 | — | — | US | disclosed |
| US-20120301551-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING NEURONAL DEATH OR NEUROLOGICAL DYSFUNCTION | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2012-11-29 | — | — | US | disclosed |
| US-20120269854-A1 | Method of Enhancing KSHV LANA1 Immunogenicity | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120232021-A1 | PEPTIDE LINKERS FOR POLYPEPTIDE COMPOSITIONS AND METHODS FOR USING SAME | SHIRE HUMAN GENETIC THERAPIES, INC. | 2012-09-13 | — | — | US | disclosed |
| US-8263362-B2 | Cytochrome P450S and uses thereof | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2012-09-11 | — | — | US | disclosed |
| US-20120209025-A1 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases | GWAG BYOUNG-JOO (KR) | 2012-08-16 | — | — | US | disclosed |
| US-20120157523-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2012071244-A1 | HIGH-THROUGHPUT, SENSITIVE DETECTION OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE | AB Sciex, LLC (US) | 2012-05-31 | — | — | WO | disclosed |
| CN-102470182-A | Albumin-fused coagulation factors for non-intravenous administration in the treatment and prophylactic treatment of bleeding disorders | CSL BEHRING GMBH | 2012-05-23 | — | — | CN | disclosed |
| US-20120096581-A1 | METHODS OF PRODUCING POLYKETIDE SYNTHASE MUTANTS AND COMPOSITIONS AND USES THEREOF | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2012-04-19 | — | — | US | disclosed |
| US-20120030835-A1 | ENGINEERING HEAT-STABLE DISEASE RESISTANCE IN PLANTS | CORNELL UNIVERSITY (US) | 2012-02-02 | — | — | US | disclosed |
| EP-1430109-B1 | CULTIVATION OF MYCOBACTERIA | NOVARTIS VACCINES & DIAGNOSTIC (DE) | 2012-01-04 | — | — | EP | disclosed |
| US-20110312529-A1 | CONFORMATIONAL PROBES AND METHODS FOR SEQUENCING NUCLEIC ACIDS | ILLUMINA, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| WO-2011159942-A1 | CONFORMATIONAL PROBES AND METHODS FOR SEQUENCING NUCLEIC ACIDS | ILLUMINA, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| US-20110311567-A1 | Immunogenically-Enhanced Polypeptides and Related Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-12-22 | — | — | US | disclosed |
| US-20110300595-A1 | MICROORGANISM FOR PRODUCING SUCCINIC ACID | ORGANO BALANCE GMBH (DE) | 2011-12-08 | — | — | US | disclosed |
| US-7994218-B2 | Simple pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use | XENOPORT, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| EP-1373476-B1 | CYTOCHROME P450S AND USES THEREOF | UNIV KENTUCKY RES FOUND (US) | 2011-06-15 | — | — | EP | disclosed |
| EP-2291523-A1 | FACTOR VIII, VON WILLEBRAND FACTOR OR COMPLEXES THEREOF WITH PROLONGED IN VIVO HALF-LIFE | CSL Behring GmbH (DE) | 2011-03-09 | — | — | EP | disclosed |
| US-7781397-B2 | Immunoaffinity purification | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-08-24 | — | — | US | disclosed |
| WO-2010071897-A2 | ENGINEERING HEAT-STABLE DISEASE RESISTANCE IN PLANTS | CORNELL UNIVERSITY (US) | 2010-06-24 | — | — | WO | disclosed |
| US-20100130354-A1 | NOVEL SEPARATION MATRIX | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2010-05-27 | — | — | US | disclosed |
| US-20100120110-A1 | CYTOCHROME P450S AND USES THEREOF | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2010-05-13 | — | — | US | disclosed |
| US-20100112552-A1 | NUCLEIC ACID-BINDING CHIPS FOR DETECTING NITROGEN DEFICIENCIES AS PART OF BIOPROCESS CONTROL | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2010-05-06 | — | — | US | disclosed |
| EP-0961833-B1 | HUMAN PLASMA HYALURONIDASE | UNIV CALIFORNIA (US) | 2010-04-14 | — | — | EP | disclosed |
| CN-101678318-A | Graft copolymer for cation-exchange chromatography | MERCK PATENT GMBH | 2010-03-24 | — | — | CN | disclosed |
| US-20100041612-A1 | Fragments of the Glucagon-Like Peptide-1 and Uses Thereof | NEW ENGLAND MEDICAL CENTER HOSPITALS, INC. | 2010-02-18 | — | — | US | disclosed |
| WO-2009156137-A1 | FACTOR VIII, VON WILLEBRAND FACTOR OR COMPLEXES THEREOF WITH PROLONGED IN VIVO HALF-LIFE | CSL BEHRING GMBH (DE) | 2009-12-30 | — | — | WO | disclosed |
| US-20090281181-A1 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases | GNT PHARMA CO., LTD. (KR) | 2009-11-12 | — | — | US | disclosed |
| US-20090240079-A1 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2009-09-24 | — | — | US | disclosed |
| CN-101461547-A | Medicinal food loach powder and preparation method thereof | KAIYING WANG (CN) | 2009-06-24 | — | — | CN | disclosed |
| US-20090149542-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING NEURONAL DEATH OR NEUROLOGICAL DYSFUNCTION | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2009-06-11 | — | — | US | disclosed |
| CN-101437414-A | Antimicrobial preparations | PURAC BIOCHEM NV (NL) | 2009-05-20 | — | — | CN | disclosed |
| CN-101426484-A | Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases | NEUROTECH CO LTD (KR) | 2009-05-06 | — | — | CN | disclosed |
| WO-2009052191-A1 | INTERNALLY MASKED NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2009-04-23 | — | — | WO | disclosed |
| US-20090082464-A1 | EXTERNALLY MASKED NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090082440-A1 | SIMPLE PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090068211-A1 | IMMUNOGENICALLY-ENHANCED POLYPEPTIDES AND RELATED METHODS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2009-03-12 | — | — | US | disclosed |
| US-20090069419-A1 | MASKED CARBOXYLATE NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090019602-A1 | MASTER ACTIVATORS OF PATHOGEN RESPONSIVE GENES | THE GENERAL HOSPITAL CORPORATION | 2009-01-15 | — | — | US | disclosed |
| EP-2004164-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING DEGENERATIVE AND INFLAMMATORY DISEASES | Neurotech Co., Ltd. (KR) | 2008-12-24 | — | — | EP | disclosed |
| EP-1984503-A1 | MODIFIED COAGULATION FACTOR VILA WITH EXTENDED HALF-LIFE | CSL Behring GmbH (DE) | 2008-10-29 | — | — | EP | disclosed |
| EP-1974215-A2 | AFFINITY CHROMATOGRAPHY MATRICES AND METHODS OF MAKING AND USING THE SAME | MILLIPORE CORPORATION (US) | 2008-10-01 | — | — | EP | disclosed |
| US-7429574-B2 | 4-heterocyclo-pyrrolo[2,3d] pyrimidine compositions and their use | OSI PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7405057-B2 | Cytochrome P450s and uses thereof | BOARD OF TRUSTEES OF THE UNIVERSITY OF KENTUCKY (US) | 2008-07-29 | — | — | US | disclosed |
| US-20080161400-A1 | USE OF FORMS OF PROPOFOL FOR TREATING DISEASES ASSOCIATED WITH OXIDATIVE STRESS | XENOPORT, INC. | 2008-07-03 | — | — | US | disclosed |
| EP-1928483-A1 | FACTOR H FOR THE TREATMENT OF CHRONIC NEPHROPATHIES AND PRODUCTION THEREOF | CSL Behring GmbH (DE) | 2008-06-11 | — | — | EP | disclosed |
| US-20080085835-A1 | RPS GENE FAMILY, PRIMERS, PROBES AND DETECTION METHODS | AUSUBEL FREDERICK M | 2008-04-10 | — | — | US | disclosed |
| WO-2008018086-A1 | MOUTH DISSOLVING PHARMACEUTICAL OR NUTRACEUTICAL COMPOSITION | BAJAJ HEALTHCARE LIMITED (IN) | 2008-02-14 | — | — | WO | disclosed |
| CN-101123878-A | L-threonine derivatives of high therapeutic index | SIGNATURE R & D HOLDINGS LLC (US) | 2008-02-13 | — | — | CN | disclosed |
| EP-1874815-A1 | MODIFIED COAGULATION FACTOR VIII WITH ENHANCED STABILITY AND ITS DERIVATES | CSL Behring GmbH (DE) | 2008-01-09 | — | — | EP | disclosed |
| US-20070298129-A1 | Compounds and compositions for treating neuronal death or neurological dysfunction | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2007-12-27 | — | — | US | disclosed |
| CN-101076351-A | Cytokine-expressing cellular vaccines for treatment of prostate cancer | CELL GENESYS INC (US) | 2007-11-21 | — | — | CN | disclosed |
| EP-1853620-A2 | ANTIMICROBIAL HEXAPEPTIDES | Helix Biomedix, INc. (US) | 2007-11-14 | — | — | EP | disclosed |
| WO-2007119973-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING DEGENERATIVE AND INFLAMMATORY DISEASES | NEUROTECH CO., LTD. (KR) | 2007-10-25 | — | — | WO | disclosed |
| CN-101049161-A | Silkworm bred in space base as source of animal protein in human dietary | BEIJING UNIV OF AERONAUTICS & (CN) | 2007-10-10 | — | — | CN | disclosed |
| WO-2007090584-A1 | MODIFIED COAGULATION FACTOR VILA WITH EXTENDED HALF-LIFE | CSL BEHRING GMBH (DE) | 2007-08-16 | — | — | WO | disclosed |
| CN-101014255-A | Antimicrobial compositions | DANISCO (DK) | 2007-08-08 | — | — | CN | disclosed |
| EP-1572991-A4 | COMPOSITIONS AND METHODS FOR HYDROXILATING EPOTHILONES | BRISTOL MYERS SQUIBB CO (US) | 2007-07-25 | — | — | EP | disclosed |
| WO-2007081851-A2 | AFFINITY CHROMATOGRAPHY MATRICES AND METHODS OF MAKING AND USING THE SAME | MILLIPORE CORPORATION (US) | 2007-07-19 | — | — | WO | disclosed |
| US-20070134228-A1 | HUMAN PLASMA HYALURONIDASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-06-14 | — | — | US | disclosed |
| US-20070125711-A1 | Novel separation matrix | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2007-06-07 | — | — | US | disclosed |
| WO-2007038995-A1 | FACTOR H FOR THE TREATMENT OF CHRONIC NEPHROPATHIES AND PRODUCTION THEREOF | CSL BEHRING GMBH (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007030706-A1 | FRAGMENTS OF THE GLUCAGON-LIKE PEPTIDE-I AND USES THEREOF | NEW ENGLAND MEDICAL CENTER HOSPITALS, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| US-7179601-B2 | Methods of identifying plant disease-resistance genes | AUSUBEL FREDERICK M | 2007-02-20 | — | — | US | disclosed |
| WO-2007002587-A2 | INHIBITORS OF EPSTEIN BARR VIRUS NUCLEAR ANTIGEN 1 | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-7148201-B2 | Use of human plasma hyaluronidase in cancer treatment | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-12-12 | — | — | US | disclosed |
| WO-2006108590-A1 | MODIFIED COAGULATION FACTOR VIII WITH ENHANCED STABILITY AND ITS DERIVATES | CSL BEHRING GMBH (DE) | 2006-10-19 | — | — | WO | disclosed |
| JP-2006271377-A | ENZYMOLYSIS PRODUCT OF ANIMAL LIVER AND FOOD CONTAINING THE SAME | NIPPON MEAT PACKERS INC | 2006-10-12 | — | — | JP | disclosed |
| CN-1834067-A | Special boron/molybdic fertilizer for peanut and prepn. thereof | INST OF ECOLOGICAL ENVIRONMENT (CN) | 2006-09-20 | — | — | CN | disclosed |
| US-7105330-B2 | Immunoglobulin for detection and isolation of preferential glycosidase; tumor diagnosis and antitumor agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-09-12 | — | — | US | disclosed |
| WO-2006086321-A2 | ANTIMICROBIAL HEXAPEPTIDES | HELIX BIOMEDIX INC. (US) | 2006-08-17 | — | — | WO | disclosed |
| US-7084323-B1 | Stress-protected transgenic plants | THE GENERAL HOSPITAL CORPORATION (US) | 2006-08-01 | — | — | US | disclosed |
| EP-1677887-A1 | NOVEL SEPARATION MATRIX | GE Healthcare Bio-Sciences AB (SE) | 2006-07-12 | — | — | EP | disclosed |
| US-7060793-B2 | Circularly permuted fluorescent protein indicators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-06-13 | — | — | US | disclosed |
| EP-1644452-A2 | ANTIFUNGAL AND ANTIBACTERIAL COATING COMPOSITIONS | McDaniel, Steven C. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20060057112-A1 | Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances and uses thereof | ICOS CORPORATION (US) | 2006-03-16 | — | — | US | disclosed |
| EP-1630229-A2 | Melanoma antigens | THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services (US) | 2006-03-01 | — | — | EP | disclosed |
| US-20060041022-A1 | Treatment of amyotrophic lateral sclerosis with nimesulide | MOUNT SINAI SCHOOL OF MEDICINE, THE | 2006-02-23 | — | — | US | disclosed |
| US-6991787-B1 | Methods of preparing bone marrow stromal cells for use in gene therapy | ALG COMPANY (US) | 2006-01-31 | — | — | US | disclosed |
| EP-1465908-A4 | COMPOSITIONS AND METHODS FOR HYDROXYLATING EPOTHILONES | BRISTOL MYERS SQUIBB CO (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20050262584-A1 | Master activators of pathogen responsive genes | SHEEN JEN | 2005-11-24 | — | — | US | disclosed |
| US-20050227296-A1 | Method for indentifying integrin antagonists | THE GENERAL HOSPITAL CORPORATION, A MASSACHUSETTS CORPORATION | 2005-10-13 | — | — | US | disclosed |
| US-20050227346-A1 | Cultivation of dispersed mycobacteria | CHIRON BEHRING GMBH & CO. (DE) | 2005-10-13 | — | — | US | disclosed |
| CN-1220487-C | Protective composite amino acid composition for kidney and its use | UNIV ZHEJIANG (CN) | 2005-09-28 | — | — | CN | disclosed |
| EP-1572991-A2 | COMPOSITIONS AND METHODS FOR HYDROXILATING EPOTHILONES | Bristol-Myers Squibb Company (US) | 2005-09-14 | — | — | EP | disclosed |
| CN-1635906-A | Method for preventing cell death using antibodies to neurofilament proteins | NYMOX CORP (CA) | 2005-07-06 | — | — | CN | disclosed |
| WO-2005042131-A1 | NOVEL SEPARATION MATRIX | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2005-05-12 | — | — | WO | disclosed |
| EP-1510525-A1 | Expression and purification of cloned human alpha-fetoprotein | MARTINEX R & D INC. (CA) | 2005-03-02 | — | — | EP | disclosed |
| US-20050043332-A1 | Pyrrolo[2,3d]pyrimidine compositions and their use | OSI PHARMACEUTICALS, INC. | 2005-02-24 | — | — | US | disclosed |
| EP-1506292-A1 | PECTATE LYASE VARIANTS | Novozymes A/S (DK) | 2005-02-16 | — | — | EP | disclosed |
| WO-2005007758-A2 | ANTIFUNGAL AND ANTIBACTERIAL COATING COMPOSITIONS | MCDANIEL C STEVEN (US) | 2005-01-27 | — | — | WO | disclosed |
| US-6841722-B1 | Nucleic acid encoding the arabidopsis SSE1 protein and a method of using it to modify plant storage reserves | THE GENERAL HOSPITAL CORPORATION (US) | 2005-01-11 | — | — | US | disclosed |
| CN-1558770-A | Method of preventing cell death using segments of neural thread proteins | ����Ī�����ɷ�����˾ | 2004-12-29 | — | — | CN | disclosed |
| EP-0749441-B1 | EXPRESSION AND PURIFICATION OF CLONED HUMAN ALPHA-FETOPROTEIN | MARTINEX R & D INC (CA) | 2004-12-22 | — | — | EP | disclosed |
| EP-1049797-A4 | REGULATION OF FUNGAL GENE EXPRESSION | MICROBIA INC (US) | 2004-12-15 | — | — | EP | disclosed |
| US-6828106-B2 | Detection and monitoring activity of preferential protease enzyme; provide polypeptide binding domain, digest, allow binding, detect signal, incubate with protease, detect modulation of signal | CYCLACEL LIMITED (GB) | 2004-12-07 | — | — | US | disclosed |
| EP-1373476-A4 | CYTOCHROME P450S AND USES THEREOF | UNIV KENTUCKY RES FOUND (US) | 2004-10-27 | — | — | EP | disclosed |
| EP-1465908-A2 | COMPOSITIONS AND METHODS FOR HYDROXYLATING EPOTHILONES | Bristol-Myers Squibb Company (US) | 2004-10-13 | — | — | EP | disclosed |
| WO-2004078978-A1 | COMPOSITIONS AND METHODS FOR HYDROXYLATING EPOTHILONES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-09-16 | — | — | WO | disclosed |
| US-20040181829-A1 | Transgenic plants expressing a MAPKKK protein kinase domain | SHEEN JEN (US) | 2004-09-16 | — | — | US | disclosed |
| US-20040172673-A1 | Expression vector comprising nucleotide sequences coding polypetide which confers resistance to pseudomonas syringae; genetic engineering and disease resistant plants | AUSUBEL FREDERICK M (US) | 2004-09-02 | — | — | US | disclosed |
| US-6780973-B1 | PURE EOTAXIN DNA SEQUENCE AND EOTAXIN POLYPEPTIDE, AND METHODS OF USING SUCH DNA AND POLYPEPTIDE TO DIRECT CHEMOTAXIS OF EOSINOPHILS; METHODS ARE PROVIDED FOR THE TREATMENT DISEASES AND DISORDERS SUCH AS INFLAMMATION AND TUMORIGENESIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2004-08-24 | — | — | US | disclosed |
| WO-2004061116-A2 | COMPOSITIONS AND METHODS FOR HYDROXILATING EPOTHILONES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-07-22 | — | — | WO | disclosed |
| EP-1430109-A2 | CULTIVATION OF MYCOBACTERIA | Chiron Behring GmbH & Co. (DE) | 2004-06-23 | — | — | EP | disclosed |
| EP-1015556-A4 | STRESS-PROTECTED TRANSGENIC PLANTS | GEN HOSPITAL CORP (US) | 2004-05-26 | — | — | EP | disclosed |
| US-20040096921-A1 | Human plasma hyaluronidase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-05-20 | — | — | US | disclosed |
| US-20040088756-A1 | RPS gene family, primers, probes, and detection method | AUSUBEL FREDERICK M (US) | 2004-05-06 | — | — | US | disclosed |
| US-6699687-B1 | SENSOR POLYPEPTIDE IS INSERTED INTO AN AEQUOREA-RELATED FLUORESCENT PROTEIN (E.G., GREEN FLUORESCENT PROTEIN (GFP)) TO FORM A CONSTRUCT, FOR FLUORESCENCE SCREENING ASSAYS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-03-02 | — | — | US | disclosed |
| US-6673586-B2 | Steroid hormone receptor interacting protein kinase | BETH ISRAEL DEACONESS MEDICAL CENTER | 2004-01-06 | — | — | US | disclosed |
| EP-1373476-A2 | CYTOCHROME P450S AND USES THEREOF | University of Kentucky Research Foundation (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030235857-A1 | Regulation of fungal gene expression | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH, A DELAWARE CORPORATION | 2003-12-25 | — | — | US | disclosed |
| WO-2003095638-A1 | PECTATE LYASE VARIANTS | NOVOZYMES A/S (DK) | 2003-11-20 | — | — | WO | disclosed |
| US-20030212265-A1 | Fluorescent protein sensors for measuring the pH of a biological sample | TSIEN ROGER Y (US) | 2003-11-13 | — | — | US | disclosed |
| US-6632602-B1 | Transgenic plants; use to alter levels of hexokinase protein expression in plants in order to repress/activate plant genes controlling physiology, metabolism, and cell development with emphasis on improved yields and quality of agricultural crops | THE GENERAL HOSPITAL CORPORATION | 2003-10-14 | — | — | US | disclosed |
| US-6627449-B1 | Nucleotide sequence encoding variants of green fluorescent protein (GFP) from Aequorea victoria whose emission intensity changes as pH varies between 5 and 10; use determining pH in region of a cell, or in a sample for example; kits | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-09-30 | — | — | US | disclosed |
| US-20030170243-A1 | Use of human plasma hyaluronidase in cancer treatment | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-09-11 | — | — | US | disclosed |
| US-20030166623-A1 | Novel steroid hormone receptor interacting protein kinase | BETH ISRAEL DEACONESS MEDICAL CENTER | 2003-09-04 | — | — | US | disclosed |
| US-20030166255-A1 | Culturing a host cell for expressing a first recombinant protein isoprenoid synthase and a second recombinant protein cytochromes, for transforming a disease resistance plants; genetic engineering | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2003-09-04 | — | — | US | disclosed |
| CN-1439364-A | Protective composite amino acid composition for kidney and its use | UNIV ZHEJIANG (CN) | 2003-09-03 | — | — | CN | disclosed |
| US-6613959-B1 | DNA sequence encoding mitogen-activated protein kinase kinase kinase (MAPKKK); used for increasing stress resistance or tolerance | THE GENERAL HOSPITAL CORPORATION | 2003-09-02 | — | — | US | disclosed |
| US-6608189-B1 | Polynucleotide encoding protein; emission intensity; substitutions within the amino acid sequence | UNIVERSITY OF CALIFORNIA | 2003-08-19 | — | — | US | disclosed |
| WO-2003057830-A2 | COMPOSITIONS AND METHODS FOR HYDROXYLATING EPOTHILONES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-17 | — | — | WO | disclosed |
| US-20030100027-A1 | Methods and compositions using coiled binding partners | COLYER JOHN (GB) | 2003-05-29 | — | — | US | disclosed |
| EP-0909314-A4 | PLANT SUGAR SENSORS AND USES THEREOF | GEN HOSPITAL CORP (US) | 2003-05-28 | — | — | EP | disclosed |
| EP-1171469-A4 | ANTI-p53 ANTIBODIES | ST VINCENTS HOSP SYDNEY (AU) | 2003-04-16 | — | — | EP | disclosed |
| US-6548743-B1 | Increasing flower production by transforming a plant to express a phosphatase domain of a dual-specificity mitogen-activated protein kinase (MAPK) phosphatase, under control of a promoter | THE GENERAL HOSPITAL CORPORATION | 2003-04-15 | — | — | US | disclosed |
| WO-2003029478-A2 | CULTIVATION OF DISPERSED MYCOBACTERIA | CHIRON BEHRING GMBH & CO. (DE) | 2003-04-10 | — | — | WO | disclosed |
| US-20030021779-A1 | Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers | DAN MICHAEL D (CA) | 2003-01-30 | — | — | US | disclosed |
| EP-1036168-A4 | PURIFICATION AND MICROSEQUENCING OF HYALURONIDASE ISOZYMES | UNIV CALIFORNIA (US) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001053793-A9 | A NOVEL STEROID HORMONE RECEPTOR INTERACTING PROTEIN KINASE | BETH ISRAEL HOSPITAL (US) | 2002-10-31 | — | — | WO | disclosed |
| US-20020157120-A1 | Circularly permuted fluorescent protein indicators | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-10-24 | — | — | US | disclosed |
| US-20020155517-A1 | Regulation of fungal gene expression | RUPP STEFFEN (DE) | 2002-10-24 | — | — | US | disclosed |
| US-6469154-B1 | ENCODED BY A NUCLEIC ACID: SENSOR POLYPEPTIDE RESPONSIVE TO A CHEMICAL, BIOLOGICAL, ELECTRICAL OR PHYSIOLOGICAL PARAMETER, AND A FLUORESCENT PROTEIN MOIETY THAT IS AFFECTED BY THE RESPONSIVENESS OF THE SENSOR POLYPEPTIDE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-10-22 | — | — | US | disclosed |
| US-20020147324-A1 | RPS gene family, primers, probes, and detection methods | AUSUBEL FREDERICK M (US) | 2002-10-10 | — | — | US | disclosed |
| US-20020138872-A1 | ACQUIRED RESISTANCE GENES AND USES THEREOF | GENERAL HOSPITAL CORPORATION, THE | 2002-09-26 | — | — | US | disclosed |
| WO-2002072758-A2 | CYTOCHROME P450S AND USES THEREOF | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2002-09-19 | — | — | WO | disclosed |
| WO-2002072782-A2 | MASTER ACTIVATORS OF PATHOGEN RESPONSIVE GENES | THE GENERAL HOSPITAL CORPORATION (US) | 2002-09-19 | — | — | WO | disclosed |
| EP-1019436-A4 | ACQUIRED RESISTANCE NPR GENES AND USES THEREOF | GEN HOSPITAL CORP (US) | 2002-09-18 | — | — | EP | disclosed |
| WO-2000071565-A9 | FLUORESCENT PROTEIN INDICATORS | UNIV CALIFORNIA (US) | 2002-07-04 | — | — | WO | disclosed |
| US-20020073447-A1 | Acquired resistance genes and uses thereof | DONG XINNIAN (US) | 2002-06-13 | — | — | US | disclosed |
| US-6403782-B1 | Nucleic acid encoding eotaxin | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2002-06-11 | — | — | US | disclosed |
| EP-0626850-B1 | DRY COMPOSITIONS FOR PREPARING SUBMICRON EMULSIONS | PHARMOS CORP (US) | 2002-05-15 | — | — | EP | disclosed |
| US-6358501-B1 | USED AS INTERFACE-ACTIVE SUBSTANCES | GOLDSCHMIDT GMBH (DE) | 2002-03-19 | — | — | US | disclosed |
| WO-2002013773-A2 | COSMETIC COMPOSITION | UNILEVER PLC (GB) | 2002-02-21 | — | — | WO | disclosed |
| EP-1171469-A1 | ANTI-p53 ANTIBODIES | ST VINCENT'S HOSPITAL SYDNEY LIMITED (AU) | 2002-01-16 | — | — | EP | disclosed |
| US-6331611-B1 | GENETICALLY ENGINEERED POLYPEPTIDE FOR USE IN PREVENTION OF AUTOLOGOUS OR ALLOGENIC BONE MARROW TRANSPLANT REJECTION; FOR DIAGNOSIS AND TREATMENT OF CANCER AND AUTOIMMUNE DISEASE | MCGILL UNIVERSITY (CA) | 2001-12-18 | — | — | US | disclosed |
| EP-0870012-B1 | EXPANSION OF BONE MARROW STROMAL CELLS | ALG COMPANY (US) | 2001-11-14 | — | — | EP | disclosed |
| EP-1141274-A2 | SOLUBLE RECEPTOR BR43X2 AND METHODS OF USING THEM FOR THERAPY | ZymoGenetics, Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1120462-A1 | Expansion of bone marrow stromal cells | Alg Company (US) | 2001-08-01 | — | — | EP | disclosed |
| WO-2001053793-A2 | A NOVEL STEROID HORMONE RECEPTOR INTERACTING PROTEIN KINASE | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2001-07-26 | — | — | WO | disclosed |
| US-6262248-B1 | DNA ENCODING AN ARABIDOPSIS THALIANA RPS2 POLYPEPTIDE IN PLANT CELLS PROVIDES RESISTANCE TO PATHOGENS | MASSACHUSETTS GENERAL HOSPITAL CORPORATION | 2001-07-17 | — | — | US | disclosed |
| WO-2000061735-A9 | MODIFICATION OF PLANT STORAGE RESERVES | GEN HOSPITAL CORP (US) | 2001-07-12 | — | — | WO | disclosed |
| US-6193963-B1 | PERITUMORAL OR INTRATUMORAL ADMINISTERING OF HUMAN PLASMA HYALURONIDASE POLYPEPTIDE IN AN AMOUNT EFFECTIVE TO SUPPRESS TUMOR GROWTH, WHEREIN POLYPEPTIDE HAS .BETA.-1,4-HYALURONIDASE ACTIVITY IN CLEAVAGE OF HYALURONM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-02-27 | — | — | US | disclosed |
| WO-2000071565-A2 | FLUORESCENT PROTEIN INDICATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-11-30 | — | — | WO | disclosed |
| US-6150176-A | GENETICALLY ENGINEERED GREEN FLUORESCENT PROTEIN WITH SPECIFIC SUBSTITUTIONS; FOR USE IN ORGANELLES AND CELLULAR COMPARTMENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-11-21 | — | — | US | disclosed |
| EP-1049797-A1 | REGULATION OF FUNGAL GENE EXPRESSION | Microbia Inc. (US) | 2000-11-08 | — | — | EP | disclosed |
| US-6140132-A | AMINO ACID SEQUENCE OF MODIFIED AEQUOREA GREEN FLUORESCENT PROTEIN HAVING SPECIFIC SUBSTITUTIONS; FOR DETERMINING PH IN CELLULAR ORGANELLES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-10-31 | — | — | US | disclosed |
| WO-2000061735-A1 | MODIFICATION OF PLANT STORAGE RESERVES | THE GENERAL HOSPITAL CORPORATION (US) | 2000-10-19 | — | — | WO | disclosed |
| US-6127607-A | Plant resistance gene family encoding resistance polypeptides having P-loop and LRR motifs | THE GENERAL HOSPITAL CORPORATION (US) | 2000-10-03 | — | — | US | disclosed |
| WO-2000056770-A1 | ANTI-p53 ANTIBODIES | ST. VINCENT'S HOSPITAL SYDNEY LIMITED (AU) | 2000-09-28 | — | — | WO | disclosed |
| US-6123938-A | HUMAN URINARY HYALURONIDASE COMPRISES A CHAIN OF A AND A CHAIN OF B POLYPEPTIDES WITH SPECIFIC AMINO ACID SEQUENCES AND FREE OF HUMAN PLASMA HYALURONIDASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-09-26 | — | — | US | disclosed |
| EP-1036168-A1 | PURIFICATION AND MICROSEQUENCING OF HYALURONIDASE ISOZYMES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-09-20 | — | — | EP | disclosed |
| US-6103525-A | FOR IMMUNOAFFINITY PURIFICATION OF ENZYME FROM HUMAN BLOOD FRACTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-08-15 | — | — | US | disclosed |
| EP-1019436-A1 | ACQUIRED RESISTANCE NPR GENES AND USES THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 2000-07-19 | — | — | EP | disclosed |
| WO-2000040716-A2 | SOLUBLE RECEPTOR BR43X2 AND METHODS OF USING THEM FOR THERAPY | ZYMOGENETICS, INC. (US) | 2000-07-13 | — | — | WO | disclosed |
| EP-1015556-A1 | STRESS-PROTECTED TRANSGENIC PLANTS | THE GENERAL HOSPITAL CORPORATION (US) | 2000-07-05 | — | — | EP | disclosed |
| EP-1007646-A1 | PROTEASE VARIANTS AND COMPOSITIONS | NOVO NORDISK A/S (DK) | 2000-06-14 | — | — | EP | disclosed |
| US-6069296-A | NUCLEOTIDE AND AMINO ACID SEQUENCES OF CAENORHABDITIS ELEGANS (NEMATODE) EGL-10 POLYPEPTIDE; DIAGNOSIS OF RELATED DISEASES; SCREENING MODULATORS; ANTIDIABETIC AGENTS; TREATMENT OF HYPERPLASIA, PSYCHIATRIC DISORDERS, CARDIOVASCULAR DISEASE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2000-05-30 | — | — | US | disclosed |
| WO-2000009724-A9 | TRANSGENIC PLANTS EXPRESSING A MAPKKK PROTEIN KINASE DOMAIN | GEN HOSPITAL CORP (US) | 2000-05-25 | — | — | WO | disclosed |
| WO-1999064592-A9 | GREEN FLUORESCENT PROTEINS FOR MEASURING THE PH OF A BIOLOGICAL SAMPLE | UNIV CALIFORNIA (US) | 2000-03-16 | — | — | WO | disclosed |
| WO-2000009656-A2 | TRANSGENIC PLANTS EXPRESSING A DUAL-SPECIFICITY MAPK PHOSPHATASE AND USES THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 2000-02-24 | — | — | WO | disclosed |
| WO-2000009724-A1 | TRANSGENIC PLANTS EXPRESSING A MAPKKK PROTEIN KINASE DOMAIN | THE GENERAL HOSPITAL CORPORATION (US) | 2000-02-24 | — | — | WO | disclosed |
| WO-1999064592-A2 | GREEN FLUORESCENT PROTEINS FOR MEASURING THE PH OF A BIOLOGICAL SAMPLE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-12-16 | — | — | WO | disclosed |
| US-5981730-A | OLIGONUCLEOTIDE SEQUENCE WHICH CODES FOR PROTEIN INVOLVED IN DISEASE RESISTANCE IN PLANTS | THE GENERAL HOSPITAL CORPORATION (US) | 1999-11-09 | — | — | US | disclosed |
| US-5962323-A | Expansion of bone marrow stromal cells | ALG COMPANY (US) | 1999-10-05 | — | — | US | disclosed |
| WO-1999029841-A1 | PURIFICATION AND MICROSEQUENCING OF HYALURONIDASE ISOZYMES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-06-17 | — | — | WO | disclosed |
| US-5908971-A | RIPENING | THE GENERAL HOSPITAL CORPORATION (US) | 1999-06-01 | — | — | US | disclosed |
| WO-1999025865-A1 | REGULATION OF FUNGAL GENE EXPRESSION | MICROBIA, INC. (US) | 1999-05-27 | — | — | WO | disclosed |
| EP-0783316-A4 | SYNTHETIC ANTIBIOTICS | CERES TECHNOLOGIES INC (US) | 1999-05-26 | — | — | EP | disclosed |
| EP-0909314-A1 | PLANT SUGAR SENSORS AND USES THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 1999-04-21 | — | — | EP | disclosed |
| WO-1999011770-A1 | PROTEASE VARIANTS AND COMPOSITIONS | NOVO NORDISK A/S (DK) | 1999-03-11 | — | — | WO | disclosed |
| EP-0870012-A4 | EXPANSION OF BONE MARROW STROMAL CELLS | ALG COMPANY (US) | 1999-03-10 | — | — | EP | disclosed |
| EP-0749441-A4 | EXPRESSION AND PURIFICATION OF CLONED HUMAN ALPHA-FETOPROTEIN | UNIV MCGILL (CA) | 1998-12-30 | — | — | EP | disclosed |
| US-5827721-A | BH55 hyaluronidase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-10-27 | — | — | US | disclosed |
| US-5824299-A | ADMINISTERING AN IP-10 POLYPEPTIDE TO DECREASE NON-NEOPLASTIC ENDOTHELIAL CELL PROLIFERATION; TREATING HEMANGIOMA, KELOIDS, PROLIFERATIVE RETINAL DISORDER, INFLAMMATION, FIBROSIS | PRESIDENT & FELLOWS OF HARVARD COLLEGE (US) | 1998-10-20 | — | — | US | disclosed |
| EP-0870012-A1 | EXPANSION OF BONE MARROW STROMAL CELLS | Alg Company (US) | 1998-10-14 | — | — | EP | disclosed |
| US-5801274-A | N- mercaptoacyl(amino acid or peptide)! compounds and S-lipophilic aliphatic carbonyl derivatives thereof as antihypertensives | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1998-09-01 | — | — | US | disclosed |
| EP-0759068-A4 | -i(RPS2) GENE AND USES THEREOF | GEN HOSPITAL CORP (US) | 1998-07-15 | — | — | EP | disclosed |
| EP-0763058-A4 | -i(RPS) GENE FAMILY, PRIMERS, PROBES, AND DETECTION METHODS | GEN HOSPITAL CORP (US) | 1998-07-08 | — | — | EP | disclosed |
| US-5770410-A | GENETIC ENGINEERED L-LACTATE DEHYDROGENASE USED FOR REDUCTION OF 2-OXA-4-PHENYL PROPANOIC ACID AND 2-OXO-4-METHYL-3-PENTENOIC ACID | GENZYME CORPORATION (US) | 1998-06-23 | — | — | US | disclosed |
| WO-1998026045-A1 | STRESS-PROTECTED TRANSGENIC PLANTS | THE GENERAL HOSPITAL CORPORATION (US) | 1998-06-18 | — | — | WO | disclosed |
| US-5766950-A | Expansion of bone marrow stromal cells | ALG COMPANY (US) | 1998-06-16 | — | — | US | disclosed |
| EP-0841935-A1 | MODULATION OF ENDOTHELIAL CELL PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1998-05-20 | — | — | EP | disclosed |
| US-5750142-A | LYOPHILIZED; CRYOPROTECTANTS; EMULSIFIERS; OIL IN WATER EMULSION | PHARMOS CORPORATION (US) | 1998-05-12 | — | — | US | disclosed |
| US-5747027-A | BH55 hyaluronidase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-05-05 | — | — | US | disclosed |
| WO-1997046678-A9 | NUCLEIC ACIDS AND POLYPEPTIDES RELATED TO PRESENILIN | — | 1998-04-16 | — | — | WO | disclosed |
| EP-0832110-A1 | ANTIVIRAL PEPTOID COMPOUNDS | Novartis AG (CH) | 1998-04-01 | — | — | EP | disclosed |
| WO-1998006748-A1 | ACQUIRED RESISTANCE NPR GENES AND USES THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 1998-02-19 | — | — | WO | disclosed |
| EP-0805687-A1 | RECOMBINANT HUMAN ALPHA-FETOPROTEIN AND USES THEREOF | MURGITA, Robert, A. (CA) | 1997-11-12 | — | — | EP | disclosed |
| WO-1997035965-A1 | PLANT SUGAR SENSORS AND USES THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 1997-10-02 | — | — | WO | disclosed |
| EP-0783316-A1 | SYNTHETIC ANTIBIOTICS | CERES TECHNOLOGIES, INC. (US) | 1997-07-16 | — | — | EP | disclosed |
| WO-1997024144-A1 | METHODS OF PREPARING BONE MARROW STROMAL CELLS FOR USE IN GENE THERAPY | ALG COMPANY (US) | 1997-07-10 | — | — | WO | disclosed |
| WO-1997024434-A1 | EXPANSION OF BONE MARROW STROMAL CELLS | ALG COMPANY (US) | 1997-07-10 | — | — | WO | disclosed |
| EP-0772669-A1 | SALINE SOLUTION FOR TREATING CONTACT LENSES | ALCON LABORATORIES, INC. (US) | 1997-05-14 | — | — | EP | disclosed |
| EP-0763058-A1 | $i(RPS) GENE FAMILY, PRIMERS, PROBES, AND DETECTION METHODS | THE GENERAL HOSPITAL CORPORATION (US) | 1997-03-19 | — | — | EP | disclosed |
| EP-0759068-A1 | $i(RPS2) GENE AND USES THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 1997-02-26 | — | — | EP | disclosed |
| WO-1997000691-A1 | MODULATION OF ENDOTHELIAL CELL PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1997-01-09 | — | — | WO | disclosed |
| US-5591891-A | PEPTIDASE INHIBITORS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1997-01-07 | — | — | US | disclosed |
| EP-0749441-A1 | EXPRESSION AND PURIFICATION OF CLONED HUMAN ALPHA-FETOPROTEIN | McGILL UNIVERSITY (CA) | 1996-12-27 | — | — | EP | disclosed |
| WO-1996040759-A1 | ANTIVIRAL PEPTOID COMPOUNDS | NOVARTIS AG (CH) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996031596-A1 | BH55 HYALURONIDASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-10-10 | — | — | WO | disclosed |
| WO-1996024063-A1 | METHODS FOR IDENTIFYING INTEGRIN ANTAGONISTS | THE GENERAL HOSPITAL CORPORATION (US) | 1996-08-08 | — | — | WO | disclosed |
| WO-1996022787-A1 | RECOMBINANT HUMAN ALPHA-FETOPROTEIN AND USES THEREOF | MURGITA ROBERT A (CA) | 1996-08-01 | — | — | WO | disclosed |
| WO-1996008264-A1 | SYNTHETIC ANTIBIOTICS | CERES TECHNOLOGIES, INC. (US) | 1996-03-21 | — | — | WO | disclosed |
| WO-1996003484-A1 | SALINE SOLUTION FOR TREATING CONTACT LENSES | ALCON LABORATORIES, INC. (US) | 1996-02-08 | — | — | WO | disclosed |
| EP-0690919-A1 | CRUCIFER ACC SYNTHASE AND USES THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 1996-01-10 | — | — | EP | disclosed |
| US-5472706-A | Forming oil in water emulsion, adding cryoprotectant amino compound, diluting, lyophilizing; for pharmaceuticals, cosmetics | PHARMOS CORP. (US) | 1995-12-05 | — | — | US | disclosed |
| EP-0690919-A4 | CRUCIFER ACC SYNTHASE AND USES THEREOF | GEN HOSPITAL CORP (US) | 1995-11-16 | — | — | EP | disclosed |
| WO-1995028423-A1 | RPS GENE FAMILY, PRIMERS, PROBES, AND DETECTION METHODS | THE GENERAL HOSPITAL CORPORATION (US) | 1995-10-26 | — | — | WO | disclosed |
| WO-1995028478-A1 | RPS2 GENE AND USES THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 1995-10-26 | — | — | WO | disclosed |
| EP-0626850-A4 | DRY COMPOSITIONS FOR PREPARING SUBMICRON EMULSIONS. | PHARMOS CORP (US) | 1995-07-26 | — | — | EP | disclosed |
| US-5384250-A | Prokaryotic cells | MCGILL UNIVERSITY (CA) | 1995-01-24 | — | — | US | disclosed |
| WO-1994028018-A2 | SYNTHETIC STERICALLY-CONSTRAINED CATALYSTS | ATASSI ZOUHAIR (US) | 1994-12-08 | — | — | WO | disclosed |
| EP-0626850-A1 | DRY COMPOSITIONS FOR PREPARING SUBMICRON EMULSIONS | PHARMOS CORPORATION (US) | 1994-12-07 | — | — | EP | disclosed |
| WO-1994017036-A1 | S-LIPOPHILIC ALIPHATIC CARBONYL [N-MERCAPTOACYL-(AMINO ACID OR PEPTIDE)] COMPOUNDS AS ANTIHYPERTENSIVE AGENTS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1994-08-04 | — | — | WO | disclosed |
| WO-1994010199-A1 | EXPRESSION AND PURIFICATION OF CLONED HUMAN ALPHA-FETOPROTEIN | MCGILL UNIVERSITY (CA) | 1994-05-11 | — | — | WO | disclosed |
| WO-1994008449-A1 | CRUCIFER ACC SYNTHASE AND USES THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 1994-04-28 | — | — | WO | disclosed |
| US-5258062-A | Ceramic packages for semiconductor devices | SHINKO ELECTRIC INDUSTRIES CO., LTD. (JP) | 1993-11-02 | — | — | US | disclosed |
| WO-1993015736-A1 | DRY COMPOSITIONS FOR PREPARING SUBMICRON EMULSIONS | PHARMOS CORP. (US) | 1993-08-19 | — | — | WO | disclosed |
| EP-0345242-A2 | Expression of gag proteins from retroviruses in eucaryotic cells | SMITHKLINE BIOLOGICALS S.A. (BE) | 1989-12-06 | — | — | EP | disclosed |
| EP-0118280-B1 | ENZYME INHIBITION | Aktiebolaget Hässle (SE) | 1989-07-12 | — | — | EP | disclosed |
| US-4772686-A | ANTICOAGULANTS | AKTIEBOLAGET HASSLE (SE) | 1988-09-20 | — | — | US | disclosed |
| US-4748116-A | LUMINOL, ISOLUMINOL | KABIVITRUM AB (SE) | 1988-05-31 | — | — | US | disclosed |
| US-4638047-A | Enzyme inhibition | AKTIEBOLAGET HASSLE (SE) | 1987-01-20 | — | — | US | disclosed |
| JP-S61100177-A | METHOD OF PRESERVING PROCESSED FOOD | FUKUNAGA KAZUJI | 1986-05-19 | — | — | JP | disclosed |
| WO-1984003507-A1 | ENZYME INHIBITION | FERRING AB (SE) | 1984-09-13 | — | — | WO | disclosed |
| WO-1984003507-A1 | ENZYME INHIBITION | FERRING AB (SE) | 1984-09-13 | — | — | WO | disclosed |
| EP-0118280-A1 | Enzyme inhibition | Aktiebolaget Hässle (SE) | 1984-09-12 | — | — | EP | disclosed |
| EP-0118280-A1 | Enzyme inhibition | Aktiebolaget Hässle (SE) | 1984-09-12 | — | — | EP | disclosed |
| US-4424354-A | MERCAPTOALKANOYL DERIVATIVES OF PEPTIDES | E. R. SQUIBB & SONS, INC. (US) | 1984-01-03 | — | — | US | disclosed |
| US-4424396-A | ARYL HALIDE, A-AMINOACID | OCCIDENTAL CHEMICAL CORPORATION (US) | 1984-01-03 | — | — | US | disclosed |
| US-4382081-A | ANTIARRTHRITIC AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1983-05-03 | — | — | US | disclosed |
| US-4382081-A | ANTIARRTHRITIC AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1983-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10912836-B2 | Synthetic antibody mimetic compounds (SyAMs) targeting cancer, especially prostate cancer | CD47, FCGR1A, FCGR2A | GLRA1 1933/4885SLC6A9 3747/4885OR51E2 2036/4885 |
| US-20090149542-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING NEURONAL DEATH OR NEUROLOGICAL DYSFUNCTION | BCL2, BAX, SMN1; SMN2 | GLRA1 1342/4885SLC6A9 2898/4885OR51E2 3507/4885 |
| US-20210338829-A1 | INTERLEUKIN 10 CONJUGATES AND USES THEREOF | IL2, CCR10, IL2RA | GLRA1 1500/4885SLC6A9 2802/4885OR51E2 3991/4885 |
| US-20210046160-A1 | Immuno Oncology Combination Therapies With IL-2 Conjugates | IL2, IL2RA, IL15 | GLRA1 2668/4885SLC6A9 4541/4885OR51E2 4465/4885 |
| US-20120157523-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, MGMT, BHMT2 | GLRA1 1691/4885SLC6A9 1861/4885OR51E2 3942/4885 |
| US-20120301551-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING NEURONAL DEATH OR NEUROLOGICAL DYSFUNCTION | BCL2, BAX, SMN1; SMN2 | GLRA1 1342/4885SLC6A9 2898/4885OR51E2 3507/4885 |
| US-20200188484-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | IL2, IL2RA, IL36G | GLRA1 2684/4885SLC6A9 4638/4885OR51E2 4522/4885 |
| US-20230416327-A1 | IMMUNO ONCOLOGY THERAPIES WITH IL-2 CONJUGATES | IL2, IL2RA, IL15 | GLRA1 2779/4885SLC6A9 4509/4885OR51E2 4430/4885 |
| US-20140051705-A1 | Morpholinoalkyl Fumarate Compounds, Pharmaceutical Compositions, and Methods of Use | FH, APC, HTT | GLRA1 2501/4885SLC6A9 3347/4885OR51E2 1896/4885 |
| US-20160082112-A1 | SYNTHETIC ANTIBODY MIMETIC COMPOUNDS (SYAMS) TARGETING CANCER, ESPECIALLY PROSTATE CANCER | CD47, FCGR1A, FCGR2A | GLRA1 1943/4885SLC6A9 3830/4885OR51E2 1723/4885 |
| US-20150197486-A9 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | FH, MGMT, BHMT2 | GLRA1 1792/4885SLC6A9 1981/4885OR51E2 4068/4885 |
| US-20130203753-A1 | MORPHOLINOALKYL FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE | FH, APC, HTT | GLRA1 2501/4885SLC6A9 3347/4885OR51E2 1896/4885 |
| US-20220016252-A1 | IMMUNO ONCOLOGY COMBINATION THERAPY WITH IL-2 CONJUGATES AND ANTI-EGFR ANTIBODIES | IL2, IL2RA, EGFR | GLRA1 1828/4885SLC6A9 3180/4885OR51E2 2521/4885 |
| US-20230302089-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | IL2, IL2RA, IL15 | GLRA1 1526/4885SLC6A9 4468/4885OR51E2 4539/4885 |
| US-20120209025-A1 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases | ALOX12, ALOX15, ALOX15B | GLRA1 2385/4885SLC6A9 1583/4885OR51E2 3349/4885 |
| US-20200399338-A1 | IL-15 Conjugates and Uses Thereof | IL15, IL15RA, IL2 | GLRA1 1409/4885SLC6A9 3476/4885OR51E2 3997/4885 |
| US-20090069419-A1 | MASKED CARBOXYLATE NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | ADSL, AASDHPPT, ACMSD | GLRA1 532/4885SLC6A9 227/4885OR51E2 2600/4885 |
| US-11701407-B2 | Cytokine conjugates for the treatment of proliferative and infectious diseases | IL2, IL2RA, IL36G | GLRA1 2684/4885SLC6A9 4638/4885OR51E2 4522/4885 |
| US-20220016249-A1 | IL-2 Conjugates and Methods of Use Thereof | IL2, IL2RA, IL15 | GLRA1 2325/4885SLC6A9 3837/4885OR51E2 4120/4885 |
| US-10117943-B2 | Synthetic antibody mimetic compounds (SYAMS) targeting cancer, especially prostate cancer | CD47, FCGR1A, FCGR2A | GLRA1 1943/4885SLC6A9 3830/4885OR51E2 1723/4885 |
| US-20240226309-A1 | HEAD AND NECK CANCER COMBINATION THERAPY COMPRISING AN IL-2 CONJUGATE AND CETUXIMAB | IL2, IL2RA, CD22 | GLRA1 3020/4885SLC6A9 3777/4885OR51E2 2506/4885 |
| US-20200181220-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | IL2, IL2RA, IL36G | GLRA1 2684/4885SLC6A9 4638/4885OR51E2 4522/4885 |
| US-20210054040-A1 | NOVEL IL-15 CONJUGATES AND USES THEREOF | IL15, IL15RA, IL5 | GLRA1 938/4885SLC6A9 2782/4885OR51E2 3568/4885 |
| US-20060041022-A1 | Treatment of amyotrophic lateral sclerosis with nimesulide | SMN1; SMN2, RANBP1, CAPN9 | GLRA1 2682/4885SLC6A9 2375/4885OR51E2 2496/4885 |
| US-11077195-B2 | IL-2 conjugates and methods of use thereof | IL2, IL2RA, IL15 | GLRA1 2325/4885SLC6A9 3837/4885OR51E2 4120/4885 |
| US-20090240079-A1 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases | ALOX12, ALOX15, ALOX15B | GLRA1 2385/4885SLC6A9 1583/4885OR51E2 3349/4885 |
| US-20190135865-A1 | AGONIST AGENTS OF CD47 INDUCING PROGRAMMED CELL DEATH AND THEIR USE IN THE TREATMENTS OF DISEASES ASSOCIATED WITH DEFECTS IN PROGRAMMED CELL DEATH | CD47, BID, CD274 | GLRA1 1639/4885SLC6A9 4751/4885OR51E2 3180/4885 |
| US-20240082359-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | IL2, IL2RA, IL36G | GLRA1 2684/4885SLC6A9 4638/4885OR51E2 4522/4885 |
| US-20190314455-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | IL2, IL2RA, IL36G | GLRA1 2684/4885SLC6A9 4638/4885OR51E2 4522/4885 |
| US-20230355737-A1 | PARTICLE COMPRISING AN RSV-F PROTEIN FOR USE IN RSV VACCINATION | CUTA, RRP12, VAC14 | GLRA1 3954/4885SLC6A9 4817/4885OR51E2 2494/4885 |
| US-20070298129-A1 | Compounds and compositions for treating neuronal death or neurological dysfunction | BCL2, BAX, SMN1; SMN2 | GLRA1 1342/4885SLC6A9 2898/4885OR51E2 3507/4885 |
| US-10610571-B2 | Cytokine conjugates for the treatment of proliferative and infectious diseases | IL2, IL2RA, IL36G | GLRA1 2684/4885SLC6A9 4638/4885OR51E2 4522/4885 |
| US-20210070827-A1 | IL-2 CONJUGATES AND METHODS OF USE TO TREAT AUTOIMMUNE DISEASES | IL2, IL2RA, IL15 | GLRA1 2034/4885SLC6A9 4185/4885OR51E2 4691/4885 |
| US-20190209696-A1 | SYNTHETIC ANTIBODY MIMETIC COMPOUNDS (SYAMS) TARGETING CANCER, ESPECIALLY PROSTATE CANCER | CD47, FCGR1A, FCGR2A | GLRA1 1933/4885SLC6A9 3747/4885OR51E2 2036/4885 |
| US-20090281181-A1 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases | ALOX12, ALOX15, ALOX15B | GLRA1 2385/4885SLC6A9 1583/4885OR51E2 3349/4885 |
| US-20210340586-A1 | Methods of Producing Full-Length Antibodies Using E. coli | MRPL21, TXNRD1, PRDX3 | GLRA1 2126/4885SLC6A9 2926/4885OR51E2 3182/4885 |
| US-20200231644-A1 | CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | IL2, IL2RA, IL15 | GLRA1 1526/4885SLC6A9 4468/4885OR51E2 4539/4885 |
| US-20200246467-A1 | IL-2 CONJUGATES AND METHODS OF USE THEREOF | IL2, IL2RA, IL15 | GLRA1 2325/4885SLC6A9 3837/4885OR51E2 4120/4885 |
| US-20050043332-A1 | Pyrrolo[2,3d]pyrimidine compositions and their use | TYMP, UMPS, ADORA3 | GLRA1 2168/4885SLC6A9 4411/4885OR51E2 4613/4885 |
| US-20090124555-A1 | USE OF HISTOGRANIN AND HISTOGRANIN-LIKE COMPOUNDS AS INHIBITORS OF P2X7 RECEPTOR FUNCTION AND AS ANTI-ARTHRITIC AGENTS | P2RX5, P2RX3, P2RX2 | GLRA1 312/4885SLC6A9 3030/4885OR51E2 1977/4885 |
| US-20130316988-A1 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases | ALOX12, ALOX15, ALOX15B | GLRA1 2385/4885SLC6A9 1583/4885OR51E2 3349/4885 |
| US-20230277627-A1 | IMMUNO ONCOLOGY COMBINATION THERAPY WITH IL-2 CONJUGATES AND PEMBROLIZUMAB | IL2, IL2RA, PDCD1LG2 | GLRA1 3650/4885SLC6A9 4281/4885OR51E2 4330/4885 |
| US-20080161400-A1 | USE OF FORMS OF PROPOFOL FOR TREATING DISEASES ASSOCIATED WITH OXIDATIVE STRESS | GLS2, CPT1A, PAOX | GLRA1 1325/4885SLC6A9 1030/4885OR51E2 3100/4885 |
| US-20100041612-A1 | Fragments of the Glucagon-Like Peptide-1 and Uses Thereof | GLP1R, IAPP, GIPR | GLRA1 268/4885SLC6A9 4288/4885OR51E2 3498/4885 |
| US-20220211877-A1 | COMPOUND FOR INTRAOPERATIVE MOLECULAR BIOIMAGING, METHOD OF MAKING THE SAME, USE THEREOF IN INTRAOPERATIVE MOLECULAR BIOIMAGING AND SURGICAL METHOD COMPRISING INTRAOPERATIVE MOLECULAR BIOIMAGING | VIM, CD68, MKI67 | GLRA1 1945/4885SLC6A9 4072/4885OR51E2 126/4885 |
| US-20090082464-A1 | EXTERNALLY MASKED NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | AASDHPPT, ADSL, NAPEPLD | GLRA1 902/4885SLC6A9 501/4885OR51E2 2366/4885 |
| US-20090082440-A1 | SIMPLE PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | ADSL, SLC19A1, SLC25A21 | GLRA1 482/4885SLC6A9 161/4885OR51E2 3647/4885 |
| US-20200330601-A1 | IL-2 Conjugates and Methods of Use Thereof | IL2, IL2RA, IL15 | GLRA1 2325/4885SLC6A9 3837/4885OR51E2 4120/4885 |
| US-20200392550-A1 | REAGENTS AND METHODS FOR REPLICATION, TRANSCRIPTION, AND TRANSLATION IN SEMI-SYNTHETIC ORGANISMS | RNGTT, MAX, POLRMT | GLRA1 1921/4885SLC6A9 2651/4885OR51E2 1773/4885 |
| US-11879145-B2 | Reagents and methods for replication, transcription, and translation in semi-synthetic organisms | RNGTT, MAX, POLRMT | GLRA1 1921/4885SLC6A9 2651/4885OR51E2 1773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.